South Dakota State University

Open PRAIRIE: Open Public Research Access Institutional
Repository and Information Exchange
Electronic Theses and Dissertations
2017

Analysis of Novel Cyanide Antidote Dimethyl Trisulfide for
Pharmacokinetic Studies, and Sulfur Mustard Metabolites for
Identification of Biomarker of Inhaled Dose
Erica Manandhar
South Dakota State University

Follow this and additional works at: https://openprairie.sdstate.edu/etd
Part of the Medicinal-Pharmaceutical Chemistry Commons

Recommended Citation
Manandhar, Erica, "Analysis of Novel Cyanide Antidote Dimethyl Trisulfide for Pharmacokinetic Studies,
and Sulfur Mustard Metabolites for Identification of Biomarker of Inhaled Dose" (2017). Electronic Theses
and Dissertations. 2166.
https://openprairie.sdstate.edu/etd/2166

This Dissertation - Open Access is brought to you for free and open access by Open PRAIRIE: Open Public
Research Access Institutional Repository and Information Exchange. It has been accepted for inclusion in
Electronic Theses and Dissertations by an authorized administrator of Open PRAIRIE: Open Public Research
Access Institutional Repository and Information Exchange. For more information, please contact
michael.biondo@sdstate.edu.

ANALYSIS OF NOVEL CYANIDE ANTIDOTE DIMETHYL TRISULFIDE FOR
PHARMACOKINETIC STUDIES, AND SULFUR MUSTARD METABOLITES FOR
IDENTIFICATION OF BIOMARKER OF INHALED DOSE

BY
ERICA MANANDHAR

A dissertation submitted in partial fulfillment of the requirements for the
Doctor of Philosophy
Major in Chemistry
South Dakota State University
2017

iii
I would like to dedicate this dissertation to my loving parents, Kamal and Ira
Manandhar. I am forever grateful for your unconditional love and support.
This dissertation would not have been possible without the love and constant
support of my husband, Ranjan Karki. You have helped me stay focused on my goals
during the most challenging times. Thank you for not only helping me dream big but also
for supporting me throughout my hard work to achieve those dreams. This achievement
and many more are dedicated to you.
I would like to thank my brother, my in-laws, family, and friends for the joy you
all bring in my life. Each of you have inspired and motivated me, and without you all, I
would not be where I am today.

iv
ACKNOWLEDGEMENTS
I would like to express my sincere gratitude and heartfelt appreciation to my
advisor, Dr. Brian A. Logue. Your guidance and support has played an instrumental role
in shaping my success in graduate school. Thank you for believing in me and constantly
reminding me of my potential.
Thank you to the members of LARGE group for the constant inspiration, support,
and guidance. I would like to thank my colleague, Adam Pay, for his work in synthesis of
compounds needed in this project.
I would like to thank my committee members, the Department of Chemistry and
Biochemistry at South Dakota State University, and all the faculty and staff for their
assistance and encouragement. My sincere gratitude goes to the institutions and agencies
that have funded my research and made the completion of my degree a possibility.

v
TABLE OF CONTENTS
ABBREVIATIONS ............................................................................................................ x
LIST OF FIGURES ......................................................................................................... xiv
LIST OF TABLES ........................................................................................................... xvi
ABSTRACT.................................................................................................................... xvii
Chapter 1. Introduction ................................................................................................... 1
1.1 Overall Significance .................................................................................................. 1
1.2 Project Objectives ..................................................................................................... 2
1.3 Classifications of CWAs ........................................................................................... 2
1.4 History and uses of CWAs ........................................................................................ 4
1.5 Cyanide: Exposure, Toxicity, Antidotes ................................................................... 5
1.5.1 Exposure to Cyanide........................................................................................... 5
1.5.2 Mechanism of toxicity and symptoms ................................................................ 7
1.5.3 Confirmation of exposure ................................................................................... 8
1.5.4 Current cyanide antidotes ................................................................................... 9
1.5.5 Novel cyanide antidotes.................................................................................... 11
1.6 Sulfur Mustard: Exposure, Toxicity, Metabolism, and Confirmation of Exposure 15
1.6.1 Exposure to Sulfur Mustard.............................................................................. 15
1.6.2 Mechanism of sulfur mustard toxicity .............................................................. 16
1.6.3 Metabolism of sulfur mustard........................................................................... 18

vi
1.6.4 Confirmation of exposure ................................................................................. 19
Chapter 2. Determination of Dimethyl trisulfide in rabbit blood using stir bar
sorptive extraction – gas chromatography mass spectrometry .................................. 22
2.1 Introduction ............................................................................................................. 22
2.2 Experimental ........................................................................................................... 26
2.2.1 Reagents and Standards .................................................................................... 26
2.2.2 Biological fluids ............................................................................................... 26
2.2.3 Sample preparation ........................................................................................... 27
2.2.4 GC-MS analysis of DMTS ............................................................................... 28
2.2.5 Calibration, quantification, and limit of detection ............................................ 29
2.2.6 Selectivity and sensitivity ................................................................................. 31
2.2.7 Recovery and matrix effects ............................................................................. 34
2.3 Results and Discussion ............................................................................................ 34
2.3.1 GC-MS analysis of DMTS from rabbit blood .................................................. 34
2.3.2 Dynamic range, limit of detection, and sensitivity ........................................... 36
2.3.3 Accuracy and precision .................................................................................... 38
2.3.4 Matrix effects and recovery .............................................................................. 39
2.3.5 DMTS storage stability..................................................................................... 40

vii
2.3.6 Analysis of DMTS exposed animals ................................................................ 43
2.4 Conclusion............................................................................................................... 44
2.5 Acknowledgements ................................................................................................. 45
Chapter 3. Identification of sulfur mustard biomarkers for correlation to inhalation
studies ............................................................................................................................... 46
3.1 Introduction ............................................................................................................. 46
3.2 Materials and Methods ............................................................................................ 50
3.2.1 Chemicals and reagents .................................................................................... 50
3.2.2 Synthesis of metabolites ................................................................................... 50
3.2.3 Characterization of prepared standards ............................................................ 54
3.2.4 Sample preparation ........................................................................................... 55
3.2.5 UHPLC-MSMS analysis .................................................................................. 55
3.2.6 Detection of biologically relevant levels from spiked plasma ......................... 56
3.2.7 Screening of metabolites from exposed swine plasma ..................................... 56
3.2.8 Validation of the method for SMO and SBSNAE in swine plasma ................. 57
3.2.9 Analysis of rat plasma samples for biomarker correlation to inhalation dose.. 59
3.3 Results and Discussion ............................................................................................ 60
3.3.1 LCMSMS analysis of plasma metabolites........................................................ 60

viii
3.3.2 Detection of metabolites at biologically relevant levels ................................... 62
3.3.3 Identification of metabolites from exposed swine plasma ............................... 63
3.3.4 Validation of the method for SMO and SBSNAE in swine plasma ................. 68
3.3.5 Correlation of biomarker concentration to inhalation dose in rats ................... 71
3.4 Conclusion............................................................................................................... 73
3.5 Acknowledgements ................................................................................................. 74
Chapter 4. Analysis of sulfur mustard oxide in plasma using chemical ionization –
gas chromatography mass spectrometry ...................................................................... 75
4.1 Introduction ............................................................................................................. 75
4.2 Materials and Methods ............................................................................................ 78
4.2.1 Chemicals and solutions ................................................................................... 79
4.2.2 Sample preparation ........................................................................................... 80
4.2.3 GC-MS analysis of SMO.................................................................................. 80
4.2.4 Calibration, quantification, and limit of detection ............................................ 82
4.2.5 Selectivity and sensitivity ................................................................................. 83
4.2.6 Matrix effects .................................................................................................... 84
4.3 Results and Discussion ............................................................................................ 84
4.3.1 GC-MS analysis of SMO.................................................................................. 84

ix
4.3.2 Limit-of-detection and linear range .................................................................. 86
4.3.3 Accuracy and precision .................................................................................... 87
4.3.4 Matrix effects .................................................................................................... 88
4.3.5 Recovery ........................................................................................................... 88
4.4 Conclusion............................................................................................................... 90
4.5 Acknowledgements ................................................................................................. 91
Chapter 5. Broader Impacts, Conclusions, and Future Work ................................... 92
5.1 Broader Impacts ...................................................................................................... 92
5.2 Conclusions ............................................................................................................. 92
5.3 Future Work ............................................................................................................ 93
References ........................................................................................................................ 94

x
ABBREVIATIONS
3-MP: 3-mercaptopyruvate
3-MST: 3-MP sulfurtransferase
AALAC: Association for the Assessment and Accreditation of Laboratory Animal Care
ATCA: 2-amino-2-thiazoline-4-carboxylic acid
ATP: Adenosine triphosphate
Cbi: Cobinamide
Cbl: Hydroxocobalamin
CE: Collision energy
CI: Chemical ionization
CIS: Cooled injection system
CWAs: Chemical warfare agents
CXP: Collision cell exit potential
Cys: Cysteine
Cyt c: Cytochrome c
DMDS: Dimethyl disulfide
DMTS-d6: Dimethyl trisulfide-d6

xi
DMTS: Dimethyl trisulfide
DP: Declustering potential
ECM: Extracellular matrix
EDTA: Ethylenediaminetetraacetic acid
EI: Electron impact
FDA: Food and Drug Administration
FT: Freeze thaw
GC: Gas chromatography
GSH: glutathione
HCN: Hydrogen cyanide
HETE: Hydroxyethylthioethyl
IACUC: Institutional Animal Care and Use Committee
IS: Internal standard
ITCA: 2-iminothiazoline-4-carboxylic acid
Kow: Octanol-water partition coefficient
LLOQ: Lower limit of quantification
LOD: Limit of detection

xii
MRM: Multiple reaction monitoring
MS: Mass spectrometry
MSMTESE: 1-methylsulfinyl-2-[2 (methylthio)ethylsulfonyl]ethane
NAD+: Nicotinamide adenine dinucleotide
PARP: Poly (ADP-ribose) polymerase
PDMS: Polydimethylsiloxane
Phe: Phenylalanine
Pro: Proline
PTV: Programmable temperature vaporization
QC: Quality control
SBESE: 1,1’-sulfonylbis [2-(ethylsulfinyl) ethane]
SBMSE: 1,1’-sulfonylbis [2-(methylsulfinyl) ethane]
SBMTE: 1,1’-sulfonylbis[2-(methylthio) ethane]
SBSE: Stir bar sorptive extraction
SBSNAE: 1,1’-sulfonylbis[2-S- (N-acetylcysteinyl) ethane]
SCN-: Thiocyanate
SIM: Selective ion monitoring

xiii
SM: Sulfur Mustard
SMO-d4: Sulfur mustard oxide-d4
SMO: Sulfur mustard oxide
SN1: 1st order nucleophilic substitution
TDG: Thiodigycol
TDGO: Thiodigycol oxide
TDU: Thermal desorption unit
TIC: Total ion chromatogram
ULOQ: Upper limit of quantification
Val: Valine
WMD: Weapons of Mass Destruction
XIC: Extracted ion chromatogram

xiv
LIST OF FIGURES
Figure 1.1. Diagram showing the electron transport chain. Cyanide binds to the Fe3+ of
the cytochrome c and results in inhibition of cellular respiration [47]. .............................. 8
Figure 1.2. Structures of cobalamin (a) and cobinamide (b). The cobalt atom in
cobalamin only has one available binding site due to the presence of
dimethylbenzimidazole ribonucleotide tail (shown in blue). Cobinamide lacks the
dimethylbenzimidazole ribonucleotide tail, which allows its cobalt atom to have two
binding sites (upper and lower) for ligands. ..................................................................... 13
Figure 1.3. Reaction showing the detoxification of cyanide (CN-) to thiocyanate (SCN-)
by DMTS. In vitro and in vivo studies suggest that DMTS is capable of metabolizing
cyanide even without the presence of a sulfur transferase enzyme like rhodanese. ......... 15
Figure 1.4. Formation of episulfonium ion as a result of first order SN1 intramolecular
cyclization. ........................................................................................................................ 18
Figure 2.1. Schematic representation of the reaction of DMTS and cyanide to form
dimethyl disulfide (DMDS) and thiocyanate. ................................................................... 26
Figure 2.2. Total ion GC-MS chromatograms of non-spiked blood (lower trace, listed as
“Blank”) and selected ion chromatograms of 1 µM DMTS (middle traces) and 1 µM
DMTS-d6 (upper traces). DMTS quantification and identification ions (m/z 126 and 111,
respectively) and DMTS-d6 quantification and identification ions (m/z 132 and 114,
respectively) are separately plotted. .................................................................................. 36
Figure 2.3. Evaluation of the ability of the IS to correct for signal loss during storage at 80 °C. (A) DMTS signal stability plotted without IS correction. (B) IS corrected DMTS
signal stability. The uncorrected DMTS signal clearly decreases from Day 0 (due to l loss
during storage and freeze-thaw process) and has high variability (due to variation in
instrument sensitivity and stir bars). The IS corrected stability remains consistent
throughout the time tested, with the IS correcting the DMTS signal for significant loss
mechanisms. ...................................................................................................................... 43
Figure 2.4. GC-MS chromatograms (SIM, m/z 126) for DMTS treated (200 mg/kg) and
untreated mice blood, and DMTS spiked and non-spiked rabbit blood. .......................... 44
Figure 3.1. Metabolic products of sulfur mustard: hydrolysis, oxidation, β –lyase
products, DNA (N7-HETEG, O6-HETEG, N3-HETEA, Bis-G) and protein adducts
(HETE-Val and HETE-Cys). ............................................................................................ 49
Figure 3.2. Reaction schemes for synthesis of SM metabolites and internal standard
(SBESE). ........................................................................................................................... 51

xv
Figure 3.3. Extracted ion chromatograms (XICs) of six plasma metabolites of SM plotted
over the time of their elution. Non-spiked swine plasma is shown in the lower trace,
whereas the upper trace shows plasma spiked with metabolites. ..................................... 62
Figure 3.4. Toxicokinetic profile of SMO in swine plasma for inhalation exposure of
SM. 19109, 19595, and 19596 designate the three individual animals used for the study.
........................................................................................................................................... 66
Figure 3.5. Plot of time vs. ln (concentration) for the individual swine (19109, 19595,
and 19596). The slopes for each animal were similar to each other. The elimination of
SMO followed a one-compartment distribution model. ................................................... 67
Figure 3.6. Toxicokinetic profile of SBSNAE in swine plasma for inhalation exposure of
SM. 19109, 19595, and 19596 designate the three individual animals used for the study.
........................................................................................................................................... 68
Figure 3.7. LOD for SBSNAE analysis in swine plasma. The lower trace shows nonspiked swine plasma, whereas the upper trace shows 10 nM spiked swine plasma. The
LOD concentration (10 nM) reproducibly produced S/N of at least 3. ............................ 69
Figure 3.8. LOD for SMO analysis in swine plasma. The lower trace shows non-spiked
swine plasma, whereas the upper trace shows 10 nM spiked swine plasma. The LOD
concentration (10 nM) reproducibly produced S/N of at least 3. ..................................... 70
Figure 3.9. Linearity of peak area ratio (SMO/IS) to exposed SM concentrations at 1 h
time-point. ......................................................................................................................... 72
Figure 3.10. Linearity of peak area ratio (SBSNAE/IS) to exposed SM concentrations at
7 h time-point. ................................................................................................................... 73
Figure 4.1. Structures of SMO (A) and SMO-d4 (B). ..................................................... 82
Figure 4.2. Overlay of extracted ion chromatograms (XICs) of m/z 175 (SMO) and m/z
181 (SMO-d4) for non-spiked and spiked swine plasma samples. The two lower traces
(black and green) show that there are no components in the plasma matrix that interfere
with analysis of either SMO or SMO-d4. The two upper traces (red and blue) show that
SMO and SMO-d4 elute at 2.68 min. ............................................................................... 86
Figure 4.3. LOD of SMO analysis using CI-GCMS; lower trace (blue) shows nonspiked swine plasma, whereas upper trace (red) shows 0.1 µM spiked swine plasma. The
LOD concentration (0.1 µM) reproducibly produced a S/N of 3. .................................... 87
Figure 4.4. Figure showing non-corrected (A) and internal standard corrected (B)
calibration curves. Both aqueous and plasma non-corrected curves showed non-linear
behavior, and could not be compared to determine matrix effect. The ratio for slopes of

xvi
corrected plasma and aqueous curve was close to 1(slope plasma/aqueous = 0.97),
indicating that the internal standard is effective in correcting any matrix effects. ........... 90

LIST OF TABLES
Table 2.1. Curve equations and R2 values for separate calibration curves prepared over a
three-day period. ............................................................................................................... 38
Table 2.2. The accuracy and precision for the analysis of DMTS in spiked rabbit blood
by SBSE-GCMS. .............................................................................................................. 39
Table 3.1. Optimized parameters for MRM transitions for SM metabolites of interest. . 61
Table 3.2. Intra- and inter- assay accuracies and precisions for analysis of SBSNAE in
spiked swine plasma. ........................................................................................................ 70
Table 3.3. Intra- and inter- assay accuracies and precisions for analysis of SMO in spiked
swine plasma. .................................................................................................................... 71
Table 4.1. Intra- and inter- assay accuracies and precisions for analysis of SMO in spiked
swine plasma. .................................................................................................................... 88

xvii
ABSTRACT
ANALYSIS OF NOVEL CYANIDE ANTIDOTE DIMETHYL TRISULFIDE FOR
PHARMACOKINETIC STUDIES, AND ANALYSIS OF SULFUR MUSTARD
METABOLITES FOR IDENTIFICATION OF BIOMARKERS OF INHALED DOSE

ERICA MANANDHAR
2017

Cyanide poisoning by accidental or intentional exposure poses a severe health
risk. The current FDA approved antidotes for cyanide poisoning can be effective, but
each suffers from specific major limitations. Dimethyl trisulfide (DMTS), a sulfur donor
that detoxifies cyanide by converting it into thiocyanate, is a promising next generation
cyanide antidote. Although a validated analytical method to analyze DMTS is not
currently available from any matrix, one will be vital for the approval of DMTS as a
therapeutic agent against cyanide poisoning. Hence, a stir bar sorptive extraction (SBSE)
gas chromatography – mass spectrometry (GC-MS) method was developed and validated
for the analysis of DMTS from rabbit whole blood. The limit of detection (LOD) using
this method was 0.06 µM with dynamic range from 0.5 – 100 µM. The method described
here allows further investigations of DMTS as a promising antidote for cyanide
poisoning.

xviii
Sulfur mustard (SM) is the most utilized chemical weapon in modern history.
Although its exposure can result in wide range of toxic outcomes, airway injury leading
to respiratory failure is the principal cause of mortality in victims. Therefore, current
investigations are underway which focus on understanding the inhalation toxicity of SM
in order to develop effective therapeutic interventions. A major challenge in inhalation
studies is the quantification of actual respiratory dose. In this report, we identified
biomarkers that have the potential for correlation to inhalation dose. Preliminary data for
correlation of two biomarkers to dose are also presented. To our knowledge, there are no
studies done in identifying SM biomarkers in inhalation exposure. Additionally, a rapid,
simple, and direct GC-MS analysis technique for an important SM biomarker, sulfur
mustard oxide (SMO), was developed and validated in swine plasma. The LOD of the
method was 0.1 µM, with a linear range from 0.5 -100 µM. The availability of this
method will allow easy and rapid diagnosis (within 15 min of exposure) of SM poisoning
especially during the asymptomatic latency period (6-24 h post-exposure).

1
Chapter 1. Introduction
1.1 Overall Significance
Chemical warfare agents (CWAs), such as cyanide and sulfur mustard, have been
weaponized and used for many years, resulting in millions of casualties and deaths [1-3].
Despite the efforts of the Chemical Weapons Convention to prohibit development,
production, stockpiling, and use of CWAs, their use on civilians, as recent as 2017 [4],
indicate the continuous threat that they pose to mankind [5]. Therefore, research on
improved toxicological understanding and the development of effective therapeutics are
critical to combat the threats of CWAs [2, 3, 6].
Approved antidotes for cyanide poisoning suffer from serious limitations [7-10],
whereas treatments for SM poisoning are currently unavailable. This necessitates the
development of novel therapeutics, which require pharmacokinetic and toxicokinetic
studies based on validated analytical methods. These studies help allow for FDA (Food
and Drug Administration) approval of novel drugs, which can potentially save lives of
CWA exposed victims. Moreover, the elucidation of the metabolic behavior of
biomarkers is necessary for correlation to “internal dose” and revealing the advantages
and disadvantages of each marker for detecting CWA exposure. To date, no biomarker
studies have been completed on inhaled SM, one of the most important routes of
exposure [11, 12]. Biomarker studies and quantification of actual respiratory dose will
improve validity of inhalation studies, which are vital in developing effective therapeutic
interventions against SM poisoning. Additionally, methods for rapid detection of early
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markers will allow for immediate diagnosis of exposure, especially during the latent
period of SM (i.e., 6-12 h post exposure when clinical symptoms are not present).
1.2 Project Objectives
The work is comprised of three main objectives: 1) Develop novel analytical
method to determine DMTS, a next generation antidote, in plasma, 2) Identify
biomarkers of inhalation exposure of SM for potential use in dose-correlation studies, and
3) Develop a simple and rapid technique for analysis of SMO, a diagnostic SM
metabolite, from plasma. Chapter 2 describes the analysis of novel cyanide antidote,
DMTS using stir bar sorptive extraction (SBSE)- gas chromatography-mass spectrometry
(GC-MS). Chapter 3 addresses the identification of biomarkers for inhalation exposure of
SM and preliminary correlation of concentration to dose. Chapter 4 details determination
of SMO from plasma using a direct and rapid GC-MS method. Chapter 5 contains
conclusions and future work.
1.3 Classifications of CWAs
Chemical warfare (CW) agents are Weapons of Mass Destruction (WMD) [13].
These compounds are extremely toxic synthetic chemicals that have a rapid onset of
action after dissemination and cause lethal or incapacitating effects on humans. They are
usually dispersed as a gas, liquid, or aerosol, or as agents adsorbed to particles that can be
made powder [13, 14].
Based on the physicochemical, physiological, and chemical properties, CW agents
can be classified in several different ways. However, the most commonly used
classification is based on the physiological effects produced by the CW agents.
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According to this classification, CW agents are mainly categorized into four distinct
subgroups: nerve agents, vesicants (blistering agents), blood agents, and choking agents
[13].
Nerve agents, including sarin, soman, tabun, and VX, are a class of highly toxic
organophosphates that affect the functioning of the nervous system [15]. Nerve agents are
more toxic than other known CWAs, and are capable of causing death within minutes to
hours of exposure, depending on concentration [16]. The highly volatile nature of nerve
agents is a key physical property contributing to their effectiveness [15, 16]. Routes of
exposure for nerve agents include inhalation, ingestion, and dermal absorption.
Choking agents, which includes a wide array of gases such as chlorine, phosgene,
ammonia, organohalides, and nitrous oxides, were among the first CW agents produced
in large quantities and were used extensively in World War II [13]. Choking agents, also
known as pulmonary agents, attack the nose, throat, and the lung tissues, primarily
causing pulmonary edema. In severe cases of exposure, the lungs can fill up with fluid,
and result in death from lack of oxygen [13].
Blistering agents, also known as vesicants, are toxic chemicals that produce
blisters or vesicles, resembling those caused by burns [13]. The chemicals in this CWA
class are toxic to skin, lungs, eyes, and mucous membranes. There are three different
subclasses within the vesicants: the mustards, the arsenicals, and the halogenated oximes.
Overall, vesicants have low lethality compared to other CW agents, but are generally
very effective in inflicting pain and producing casualties. Vesicants, mainly sulfur
mustard, is one of the most widely used CWA, because of its ability to degrade the
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performance and efficiency of soldiers by incapacitating them [13, 17]. The burns caused
by vesicants are comparable to thermal burns, however takes longer time to heal.
Blood agents, which mainly include the cyanides, get transported within the body
via distribution of blood, and function by inhibiting the ability of cells to utilize and
transfer oxygen [18]. These agents are also known as systemic agents [13, 19].
1.4 History and uses of CWAs
The use of chemical warfare agents dates back to the 19th century [13]. Although,
historical evidence shows that the use of poisonous extracts from plants were prevalent
throughout the Middle Ages and Renaissance, the practice of deploying chemicals on the
battlefield only started in 1915 [1]. CWAs, such as phosgene, sulfur mustard, and
lewisites, used in World War I caused 100,000 deaths and 1.2 million casualties. During
World War II more than a million deaths were reported due to the use of hydrogen
cyanide (Zyklon B) in extermination camps by the Nazis [2].
In recent times, CWAs were used in Iran-Iraq war, and during attacks by a
Japanese cult in Motsumoto (1994) and the Tokyo subway system (1995) [20]. More
recently, strong evidences suggest the use of CWAs such as mustard and chlorine gas in
Syria (2015) by Islamic State (IS) militants [21].
Although a wide variety of CWAs exist and are of public health and safety
concern, this work is focused on cyanide, a blood agent, and sulfur mustard, a vesicant.
The following sections will elaborate in the exposure, toxicity, treatments, and methods
used for analysis of cyanide and sulfur mustard.

5
1.5 Cyanide: Exposure, Toxicity, Antidotes
1.5.1 Exposure to Cyanide
Exposure to cyanide can be caused from natural and anthropogenic sources, or
from illicit use of cyanide as a poison [10, 22-25]. Natural sources include release of
cyanide into the environment from volcanoes, fungi, bacteria, and plants [26]. Volcanic
eruptions can release hydrogen cyanide gas into the atmosphere, which contaminates air
and water for miles [26]. Several species of bacteria, fungus, and algae, can also release
cyanide into the environment at low concentrations [27]. However, the major natural
source of cyanide is cyanogenic plants, which synthesize compounds called cyanogens
that produce cyanide upon hydrolysis [28]. Over 800 species of edible plants and fruits,
including cassava, almonds, sweet potatoes, yams, peaches, apples, apricots, pears, lima
beans, flax seeds, bamboo shoots, etc., have been identified as cyanogenic [29, 30]. For
instance, cassava, a staple food in several parts of Africa, contains enough cyanogens that
daily consumption of a cassava-rich diet can be equivalent to about half the lethal dose of
cyanide [31].
Exposure to cyanide from anthropogenic sources involve occupational exposures
during industrial processes (electroplating, plastic processing, mining) and inhalation of
hydrogen cyanide gas from fires/smoke (i.e. burning of acrylonitrile, polyurethane, wool,
silk, rubber, and cigarettes produces HCN) [32, 33]. Hydrogen cyanide, which is used to
prepare different salts of cyanide, is produced worldwide at an estimated amount of 1.4
million tons annually [22]. Extraction of a desired metal from soil or rocks is one of the
major uses of cyanide due to its strong binding capacity to gold, silver, zinc, etc. [34].
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Other common uses of cyanide include synthesis of pigments, pesticides, plastics, dyes,
and insulation. Although occupational exposure of cyanide is of major concern, the
leading cause of exposure from anthropogenic sources can be attributed to inhalation of
smoke from cigarettes [35] and household or industrial fires [36]. Incomplete combustion
of nitrogen containing compounds (e.g., plastic, wool, silk) produces cyanide-containing
smoke during building fires [36]. Cyanide develops when the temperature reaches 315 °C
(600 °F), and is released as hydrogen cyanide gas. It is reported that the majority of
deaths due to smoke inhalation during fires are caused by cyanide poisoning instead of
poisoning from carbon monoxide [37]. In 2015, a deadly explosion in a warehouse
containing 700 tons of sodium cyanide, severely contaminated air and water in Tianjin,
China. After the explosion, cyanide levels in affected zones soared up to 365 times higher
than the safety limit [38]. It is not certain if the death of 115 people during this tragic
event was a direct result of cyanide exposure. However, thousands of dead fish found on
the shore of a contaminated river stoked fears in citizens regarding the short- and longterm health effects of this exposure [38].
Apart from exposure to cyanide due to natural and anthropogenic sources, humans
can also be exposed to it due to its illicit use as suicide, homicide, and chemical warfare
agent [39]. Although the use of cyanide as poison dates back to earlier times, cyanide was
first used as a large-scale chemical weapon during World War I. In more recent times,
cyanide was used during the Iran-Iraq war in the late 1980s and in the Tokyo subway
attack in 1995 [40, 41]. Cyanide was also used to poison a lottery winner in 2012 [42, 43]
and a Pittsburgh physician in 2013 [44].
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1.5.2 Mechanism of toxicity and symptoms
Cyanide (LD50 = 1.5 mg/kg via oral exposure, LC50 = 524 ppm for a 10 min
inhalation exposure to HCN) is a rapidly acting, highly toxic compound [10, 22, 23]. The
high toxicity of cyanide can be attributed to its strong affinity for ferric ion (Fe3+), which
is a common metallic cofactor in metalloenzymes [10, 22]. The main target during
cyanide exposure is cytochrome c oxidase, which is the last mitochondrial enzyme found
in complex IV of the electron transport chain (Figure 1.1). Cytochrome c oxidase is
responsible for carrying electrons to molecular oxygen, thereby reducing it to water
(Equation 1.1) [25]. Additionally, it also maintains an electrochemical gradient of H+
ions, which is essential in the production of adenosine triphosphate (ATP). However,
when cyanide binds to the cytochrome c oxidase, it cannot transfer its electrons,
inhibiting the cellular respiration [37, 45]. Furthermore, the gradient of H+ ions disrupts,
halting the ATP synthesis. Therefore, in order to compensate for the loss of ATP, glucose
is broken down via the glycolysis pathway, which uses nictotinamide adenine
dinucleotide (NAD+). In order to replenish the lost NAD+, fermentation of lactic acid
occurs under hypoxic conditions, leading to the formation of large amounts of lactic acid.
The increase in lactic acid concentration in blood decreases the pH of the body, which
impairs several other physiological processes, ultimately leading to cell death [46].
4 Cyt c reduced + 8H . + O0 ↔ 4 Cyt c oxidized + 4H . + 2H0 O

(1.1)
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Figure 1.1. Diagram showing the electron transport chain. Cyanide binds to the Fe3+ of
the cytochrome c and results in inhibition of cellular respiration [47].
1.5.3 Confirmation of exposure
Determination of cyanide exposure can be accomplished by direct analysis of
cyanide or by analysis of its metabolites [22]. Direct analysis of cyanide may be the only
way to confirm exposure within the initial minutes following exposure [48, 49].
However, it has several limitations due to high volatility, reactivity, and also short halflife of cyanide in biological fluids, making it difficult to detect once a certain amount of
time has elapsed following exposure [50, 51]. Therefore, indirect determination of
exposure is performed by analyzing cyanide metabolites that are generally longer-lived in
vivo and are more stable under normal storage conditions than cyanide [48, 52]. The
major metabolites of cyanide that have been detected from urine, saliva, tissue, and blood
are thiocyanate (SCN-) and tautomers 2-amino-2-thiazoline-4-carboxylic acid (ATCA)
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and 2-iminothiazolidine-4-carboxylic acid (ITCA) [53-56]. Additionally,
cyanocobalamin and cyanide-protein adducts have been evaluated [18].
1.5.4 Current cyanide antidotes
There are currently three U.S. Food and Drug Administration (FDA) approved
antidotes for cyanide [10, 57]. The different classes of antidotes differ in their
detoxification mechanism. Typically, an ideal antidote is expected to have properties
such as rapid onset of action, capability of neutralizing cyanide without interfering with
cellular oxygen transport, safe to administer to victims of smoke inhalation, not harmful
if given to a non-poisoned patient, and ease of administration without the need of special
training or equipment. The detoxification mechanism and properties of the three FDA
approved antidotes will be discussed below.
1.5.4.1 Hydroxocobalamin
Hydroxocobalamin (Cbl), also known as vitamin B12, was approved by FDA for
treatment of cyanide poisoning in 2006 [10, 57, 58]. Cbl is cobalt-containing compound
that detoxifies cyanide by direct sequestration [59, 60]. Due to the high affinity of cobalt
towards cyanide, Cbl directly binds with cyanide by replacing its hydroxyl ligand,
thereby allowing the cytochrome c oxidase to return to its normal function during cellular
respiration [59, 61]. This process leads to the formation of cyanocobalamin, which is
excreted from the body in the urine [61]. The properties of Cbl that makes it ideal as an
cyanide antidote are: i) it has a rapid onset of action, ii) its detoxification process does not
compromise the oxygen carrying capacity of blood, iii) it can be administered to smoke
inhalation victims, and iv) it has mild side effects [61]. Despite the advantages of Cbl, its
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major limitation is the need for high effective doses [57]. One molecule of Cbl is required
to sequester one molecule of cyanide; therefore, due to the 50:1 Cbl:cyanide molecular
weight ratio, the recommended dose of Cbl is 5g (administered over 15 min) [8]. Due to
the large dosage, Cbl must be administered by IV, which severely limits its applicability
in cases of mass casualty situations.
1.5.4.2 Sodium nitrite
Sodium nitrite detoxifies cyanide via two routes i) indirect sequestration and ii)
cyanide displacement [62]. Nitrite (classified as a methemoglobin generator) converts
hemoglobin, which has low affinity to cyanide, to methemoglobin, which has a relatively
high affinity towards cyanide [62]. Methemoglobin serves as a temporary binding site for
cyanide, decreasing the presence of free cyanide in the bloodstream. The recently
suggested cyanide displacement mechanism of action is postulated to occur as nitrite is
converted to nitric oxide, which then displaces cyanide bound to the cytochrome c
oxidase [62, 63]. With either of the detoxification mechanism, the major limitation of
sodium nitrite is the production of methemoglobin [63]. Excessive methemoglobin is
toxic to the body and can lead to headache, cyanosis, fatigue, coma, and even death [10].
Furthermore, administration of sodium nitrite can be fatal for victims of smoke inhalation
as it further reduces the oxygen carrying capacity of the blood [62].
1.5.4.3 Sodium thiosulfate
Sodium thiosulfate is the only FDA approved sulfur donor cyanide antidote [10].
It detoxifies cyanide by donating sulfur and converting cyanide into minimally toxic and
renally excreted thiocyanate [64]. This detoxification mechanism is dependent on a sulfur
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transferase enzyme, rhodanese. Rhodanese has limited availability in the body [9], with
very low/no availability in some vital organs such as heart and brain. Therefore, these
organs are susceptible to cyanide poisoning even upon administration of thiosulfate [9,
65]. Due to this major drawback, sodium thiosulfate is only useful as combination
therapy [23, 66]. Apart from high rhodanese dependency, sodium thiosulfate is also
limited due to its short biological half-life and relative low sulfur donor activity [10].
Furthermore, the inorganic thiosulfate has limited lipophilicity as a result of its anionic
charge, which results in limited transport across cell membranes in order to reach the
endogenous rhodanese within mitochondria.
1.5.5 Novel cyanide antidotes
Considering the serious limitations in each of the available antidotes, several
investigations have been in progress for the next generation of cyanide therapeutics. The
three major ones that show a good promise in overcoming the current drawbacks are 3mercaptopyruvate (3-MP), cobinamide (Cbi), and dimethyl trisulfide (DMTS).
1.5.5.1 Cobinamide (Cbi)
Cobinamide is the penultimate precursor during the biological synthesis of
hydroxycobalamin, and is seen to have several advantages over hydroxycobalamin as a
cyanide antidote [8]. Cbi has a much higher affinity to cyanide, with Ka overall of ~ 1022
M-1 compared to a Ka of 1012 M-1 for hydroxocobalamin [67]. The higher affinity can be
explained by the difference in structures of the two molecules. Unlike Cbl, Cbi lacks the
dimethyl-benzimidazole ribonucleotide tail coordinated to the cobalt atom in the lower
axial position (Figure 1.2, blue portion of the structure), which allows it to have two
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binding site for ligands: above and below the plane of the corrin ring [68]. Therefore, it is
capable of binding two moles of cyanide per mole Cbi. Comparatively, one mole of
cyanide is bound per mole of Cbl [8]. Furthermore, in aqueous solution, Cbi exists as
aquohydroxocobinamide, which is at least five times more soluble in water than Cbl [8].
The high binding affinity of Cbi means that it can be administered in a smaller dose (11.5 g), which makes it more practically feasible than Cbl [8]. Additionally, the relatively
high water solubility allows the possibility of intramuscular administration, which makes
it a good candidate for mass casualty events [8, 69].

a.
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b.
b.

Figure 1.2. Structures of cobalamin (a) and cobinamide (b). The cobalt atom in
cobalamin only has one available binding site due to the presence of
dimethylbenzimidazole ribonucleotide tail (shown in blue). Cobinamide lacks the
dimethylbenzimidazole ribonucleotide tail, which allows its cobalt atom to have two
binding sites (upper and lower) for ligands.
1.5.5.2 3-mercaptopyruvate (3-MP)
3-MP is similar to sodium thiosulfate in that it also acts as a sulfur donor and
detoxifies cyanide by conversion into thiocyanate [70]. However, instead of being
dependent on rhodanese, 3-MP is catalyzed by 3-MP sulfurtransferase (3-MST), which is
readily available in liver, kidneys, heart, brain, and lungs. The abundance of 3-MST
reduces the vulnerability of these organs to cyanide toxicity upon administration of 3-MP
[71]. Additionally, unlike rhodanese, 3-MST is distributed in both cytosol and
mitochondria, allowing cyanide detoxification to occur in both. Despite the advantageous
properties of 3-MP, its major limitation is that it readily degrades in blood [66, 72]. In
order to overcome this drawback, several prodrugs of 3-MP are currently being
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investigated, one of which is sulfanegen [71, 72]. Developed in the early 1990s,
sulfanegen is a water-soluble prodrug of 3-MP. It is a dimer, which dissociates nonenzymatically into two 3-MP molecules in physiological condition [71]. It also
overcomes the drawback of low stability of 3-MP, which makes it an ideal choice as an
antidote.
1.5.5.3 Dimethyl trisulfide (DMTS)
DMTS, which detoxifies cyanide by converting it into thiocyanate, is suggested as
the most promising next-generation sulfur donor for treatment of cyanide poisoning [10].
Unlike the current sulfur-donor thiosulfate, DMTS can effectively function with or
without rhodanese [73]. Additionally, DMTS is highly lipophilic, which permits effective
penetration through the cell membrane and the blood brain barrier, allowing better
antidotal efficacy than thiosulfate [74]. Recent in-vitro studies have shown that DMTS is
43 times more effective than thiosulfate at detoxifying cyanide in presence of rhodanese
[73]. Whereas, in absence of rhodanese, it is 79 times more effective, confirming that
DMTS is less dependent on the enzyme [73]. Results from in-vivo studies are consistent
with these findings, suggesting that DMTS is superior as a cyanide therapeutic than
thiosulfate [74].
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Although the mechanism of detoxification in the absence of rhodanese is not fully
understood, it is evident that DMTS is effective. The reaction by which DMTS converts
cyanide into thiocyanate is shown in Figure 1.3.

S

S
S

CN

-

with or without
Rhodanese

S

S

SCN-

Figure 1.3. Reaction showing the detoxification of cyanide (CN-) to thiocyanate (SCN-)
by DMTS. In vitro and in vivo studies suggest that DMTS is capable of metabolizing
cyanide even without the presence of a sulfur transferase enzyme like rhodanese.
1.6 Sulfur Mustard: Exposure, Toxicity, Metabolism, and Confirmation of Exposure
1.6.1 Exposure to Sulfur Mustard
Bis(2-chloroethyl)sulfide, commonly known as sulfur mustard (SM), was first
synthesized in 1822 by Depretz, by reacting ethane and sulfur dichloride (Equation 1.2)
[5]. However, the vesicating properties of SM were not mentioned during or after the
synthesis. In 1860, Niemann followed the same procedure and reported that even at trace
amounts the synthesized chemical when brought in contact with skin caused pain and
blisters after several hours [5]. Later, Clark and Fischer synthesized SM by reacting
thiodigycol with hydrochloric acid (Equation 1.3) [5]. Clark suffered burns when a flask
broke during the synthesis process, which caused him to be hospitalized for 8 weeks. The
mention of this incident allegedly inspired the German Chemical Society to deploy SM
for the first time as a chemical weapon in 1917 during the course of the First World War.
Upon deployment, 4,000 deaths of British armed forces and over 16,000 nonfatal injuries
were reported as a result of SM poisoning during the course of World War I [5, 75].
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SCl0 + 2C0 H9 → (Cl − CH0 − CH0 )0 S

(1.2)

(HO − CH0 CH0 )0 S + 2HCl → (Cl − CH0 CH0 )0 S + 2H0 O

(1.3)

Since the First World War, SM has been deployed in several combat situations,
such as United Kingdom against the Red Army (1919), Spain in Morocco (1921-1927),
Italy in Libya (1930), Soviet Union against Japan (1930), Italy against Abyssinia (19351940), Poland against Germany, Germany against Soviet Union and Poland, Japan
against China during Second World War, and Egypt against Yemen (1963-1967) [5].
More recently, evidence suggests the use of SM in Iraq vs. Kurdistan, Iraq vs. Iran, and in
Syria (2015) by Islamic State (IS) militants [76].
1.6.2 Mechanism of sulfur mustard toxicity
SM can enter the body through various routes including inhalation, ingestion, and
absorption through the skin or eyes. The high lipophilicity of SM allows it to rapidly
penetrate through the hair follicles and sweat glands of skin and mucous membranes [77].
SM greatly affects moist body parts such as eyes, mouth, respiratory tract, scrotum, and
anus [77, 78]. Inhalation of its aerosol or vapor produces a serious upper respiratory tract
irritation [78] and the odor of SM does not provide adequate warning for detection. The
LCt50, which is the product of concentration and time that is lethal to 50% of the
exposed population via inhalation, is approximately 1500 mg-min/m3 [5].
The acute effects of SM are usually delayed, with no signs or symptoms in the
first hour. Within 2-6 hours post-exposure, typical signs of nausea, headache, fatigue,
reddening of the face and neck, soreness of throat, inflammation of eyes, etc. become
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severe [5]. Skin inflammation and blistering, accompanied by coughing with pus,
becomes marked within the 24 hours after exposure. In severe cases, death may be caused
within days or weeks [5]. Whereas in less severe cases, the burns heal slowly with
increased vulnerability to infections.
The toxicity of SM can be attributed to its ability to readily alkylate nucleophilic
sites (i.e., it is capable of replacing a proton in another molecule by an alkyl cation) [79,
80]. After passing through the cellular membrane, one chloroethyl side chain undergoes a
first–order (SN1) intramolecular cyclization, releasing the chloride and forming a
positively charged ethylsulfonium ring (Figure 1.4) [80]. This intermediate rapidly reacts
with nucleophilic groups (sulfhydryls, phosphates, ring nitrogens, and carboxyls) present
in DNA, RNA, and proteins, resulting in irreversible alkylation and cell death [79, 81].
The most important target is the DNA. All bases of DNA are susceptible to alkylation,
especially the N7 position of guanine because it is the most negative site within DNA
bases [82]. DNA damage can lead directly to cell death or activate poly(ADP-ribose)
polymerase (PARP) and other repair enzymes. Over-activation or higher levels of PARP
can lead to apoptotic or necrotic cell death, whereas mild levels may be beneficial to cell
survival as it triggers DNA repair mechanisms.
The vesicating activity of sulfur mustard can also be attributed to the alkylation of
cytoskeletal, extracellular matrix (ECM), and cell anchoring–related matrix proteins. This
process can weaken and interfere with the ability of basal keratinocytes to maintain vital
connections with the basement membrane, which ultimately leads to epidermal-dermal
separation, cell death, and formation of blisters.

18
Finally, sulfur mustard also targets sulfhydryl-containing proteins, such as
glutathione (GSH), which plays a major role in maintaining a redox homeostasis in the
tissues. The depletion of GSH initiates oxidative stress, which leads to lipid peroxidation
and other oxidative cellular damage.
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Figure 1.4. Formation of episulfonium ion as a result of first order SN1 intramolecular
cyclization.
1.6.3 Metabolism of sulfur mustard
There are four SM metabolic routes identified in animal models [5, 79]. The first
route can be considered direct chemical transformations resulting in β-chloroethyl
sulfoxide (SMO) from direct oxidation of SM, thiodigycol (TDG) from direct hydrolysis
of SM, and thiodiglycol sulfoxide (TDGO) from oxidation of TDG [5, 79]. The second
route involves an initial reaction of SM with two molecules of glutathione. The bisglutathione is metabolized into bis-cysteinyl conjugate followed by β-lyase cleavage of
cysteinyl C-S bond and a subsequent methylation and oxidation of the thiol, resulting in
1,1’ -sulfonylbis[2-S- (N-acetylcysteinyl) ethane] (SBSNAE), 1,1’ -sulfonylbis[2(methylthio) ethane] (SBMTE), 1-methylsulfinyl-2-[2- (methylthio)ethylsulfonyl]ethane
(MSMTESE) and 1,1’ - sulfonylbis [2-(methylsulfinyl) ethane] (SBMSE) [5, 83]. The
third route involves reaction of SM with DNA at nucleophilic sites resulting in formation
of SM-DNA adducts [82]. Finally, the last route involves reaction with amino acid
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residues present in proteins, resulting in formation of some major adducts, such as an
HETE-valine adduct of hemoglobin and an HETE-cysteine adduct of albumin [5].
1.6.4 Confirmation of exposure
Detection of free sulfur mustard in biological fluids such as urine, plasma, blood, etc.
is highly unlikely due to its extensive metabolism via rapid hydrolysis, oxidation, and
reactions with glutathione and nucleophilic sites in the body [84]. Therefore, the
metabolites as well as alkylated macromolecules are generally exploited to determine
exposure to SM. The hydrolysis, oxidation, and β-lyase metabolites appear in biological
specimens within 15 min of exposure and are ideal for diagnostic purposes. However,
these metabolites undergo relatively rapid elimination (within 5-10 days) [82] and cannot
be used as long-term markers. In contrast, adducts to macromolecules (DNA and
proteins) are present for relatively long times (30-90 days) post-exposure and can be used
for verification of exposure long after the event [82].
The analysis of urinary metabolites in SM-exposed rats were initially reported by
Black et al., where they identified oxidative and hydrolysis metabolites SMO, TDG,
TDGO, and glutathione-derived metabolites SBSNAE, SBMSE, MSMTESE, and
SBMTE [79]. Several analytical methods have been developed over the years for analysis
of these metabolites in urine. Quantification of TDG and TDGO has been typically
accomplished by derivatization followed by analysis using gas chromatography-tandem
mass spectrometry (GC-MS/MS) [85-88]. However, several studies suggested that TDG
and TDGO are not unequivocal markers of poisoning, as low concentrations (usually
<10ng/mL, but sometimes higher) of TDG and TDGO are observed in urine samples of
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animals [89] and humans [90, 91]. In fact, in some studies performed, TDG
concentrations in exposed and unexposed individuals had a considerable overlap [92].
Although TDG and TDGO are not definitive markers of SM exposure, their presence in
combination of other metabolites can help confirm a potential exposure.
β-lyase metabolites (SBMSE, MSMTSESE, SBMTE), which are unequivocal
markers for SM poisoning, were initially analyzed via GC-MS by reducing SBMSE and
MSMTESE into a single analyte, SBMTE, using titanium (II) chloride [88, 93]. More
recently, methods have been developed to analyze these markers as separate individual
entities using LC-MS/MS [83]. The β-lyase and oxidation/hydrolysis products have
mainly been studied in urine samples until Li et al. in 2013 developed a simultaneous
method for analysis of the seven metabolites (SMO, TDG, TDGO, SBMSE, MSMTESE,
SBMTE, and SBSNAE) from plasma [89]. Li et al. showed that all of the seven
metabolites were present in the plasma of rats that were exposed to SM. The analysis of
metabolites is simpler and involves less time-consuming steps compared to the analysis
of SM adducts.
Retrospective and forensic detection for SM poisoning is achieved by analyzing
DNA and proteins for SM adducts. Analysis of these macromolecules is typically
performed by three different approaches [80]. The first approach involves analysis of the
entire alkylated protein or DNA with intact SM adduct(s). In the second approach,
macromolecules can be enzymatically or chemically digested to produce a smaller
fragment which retain the adduct. Finally, the third approach involves cleaving the adduct
from the macromolecule and analyzing the unbound adduct as a free metabolite.
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Typically, analysis of protein adducts are chosen over analysis of DNA adducts, as
protein adducts are expected to have a much longer half-life, with life spans varying from
several weeks to months [94, 95]. Furthermore, the detection of protein adducts is more
sensitive and is typically advantageous in determining single, protracted, and intermittent
exposure at low concentrations [95]. There are two main protein adduct based methods,
which have been significantly improved over the years. Detection of adducts of SM to
albumin involves a pronase digestion of SM alkylated albumin, which results in
formation of (S-2-hydroxyethylthioethyl)-Cys-Pro-Phe, known as the [(S-HETE)-CysPro-Phe] [96]. This tripeptide product can be analyzed via liquid chromatography-tandem
mass spectrometry (LC-MS-MS). SM-adducted hemoglobin is detected as a HETE-Val
adduct after Edman degradation, which involves selective cleaving of the N-terminal
valine adduct to hemoglobin [97]. It is important to note than albumin adducts undergo
faster elimination than hemoglobin adducts (half-life of albumin is 20-25 days, compared
to 120 days for hemoglobin), which limits its utility to only a few weeks after exposure
[98].
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Chapter 2. Determination of Dimethyl trisulfide in rabbit blood using stir bar sorptive
extraction – gas chromatography mass spectrometry
2.1 Introduction
Cyanide (LD50 = 1.5 mg/kg, oral route, LC50 = 524 ppm for a 10 min inhalation
exposure to HCN) is a rapidly acting, highly toxic compound that inhibits cytochrome c
oxidase and subsequently causes cellular hypoxia, which may eventually result in death
[10, 22-25, 33]. It can be introduced into the body by a number of different ways, such as
consumption of cyanogenic plants and fruits [28-30] (e.g., cassava roots, yam, sorghum,
bitter almonds), inhalation of hydrogen cyanide gas from fire [99] (i.e., burning of
acrylonitrile, polyurethane, wool, silk, rubber produces HCN) and cigarette smoke,
occupational exposures (e.g., the 2015 warehouse explosion in Tianjin, China [100, 101])
and from use of cyanide as a suicide, homicide, or chemical warfare agent [32, 102, 103]
(e.g., in World War I, II, Tokyo subway attack, etc. [22]). The availability of cyanide, due
to its versatile use in industrial processes (e.g., electroplating and plastic processing) and
its rapidly acting nature, makes it an important and ever-growing threat to mankind [22,
104]. Currently, there are three major classes of cyanide therapeutics that are approved by
the U.S. Food and Drug Administration (FDA): methemoglobin generators, direct
sequestering agents, and sulfur donors [10, 57, 105, 106].
Sodium nitrite, primarily classified as a methemoglobin generator, is generally
agreed to function by indirect sequestration of cyanide [62]. Nitrite oxidizes ferrous (2+)
iron to ferric (3+) iron in hemoglobin to form methemoglobin, which strongly binds
cyanide to form cyanomethemoglobin. Methemoglobin serves as a temporary binding site
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for cyanide ion, and thus transiently decreases free cyanide in the bloodstream. Another
recently proposed alternative mechanism of action is the conversion of nitrite to nitric
oxide, which can then displace cyanide bound to cytochrome c oxidase [63, 107]. After
displacement, cyanide is subsequently converted to less harmful compounds through
normal metabolism or neutralized via a combination therapy (e.g., thiosulfate) [107].
With either detoxification mechanism, the major limitation of sodium nitrite is the
production of methemoglobin. Excessive methemoglobin production (>30%) is a health
risk, especially in children, leading to headaches, cyanosis, fatigue, coma, and even death
[57]. Additionally, conversion of hemoglobin to methemoglobin lowers the oxygen
carrying capacity of the blood, which can exacerbate carbon monoxide-induced reduction
in oxygen carrying capacity in smoke-inhalation victims [10, 62].
While sodium nitrite indirectly binds cyanide, hydroxocobalamin acts by directly
sequestering cyanide [10, 59, 108]. The high affinity of cyanide towards the cobalt atom
in hydroxocobalamin allows the formation of cyanocobalamin, which is easily excreted
from the body in the urine. Although administration of hydroxocobalamin produces only
mild side effects, it requires a high dose for optimum therapeutic effect (5 g administered
over 15 min) [108]. Therefore, hydroxocobalamin typically needs to be administered
intravenously by trained personnel over a long period of time, which severely limits its
applicability during mass casualty events [10, 57].
Sodium thiosulfate, the third class of cyanide antidote, is the only currently
approved sulfur donor for treatment of cyanide poisoning. It donates a sulfur to cyanide,
converting it to minimally toxic and renally excreted thiocyanate [64, 65]. Although
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sodium thiosulfate has few adverse effects, its antidotal activity is mainly limited by its
short biological half-life, small volume of distribution, and its dependence on rhodanese
to aid sulfur transfer [10]. Rhodanese is a sulfur transferase enzyme primarily located in
mitochondria of the liver and kidneys, with limited availability in the brain, an organ
most susceptible to cyanide-induced histotoxic anoxia. The limited lipophilicity of
thiosulfate as a result of its anionic charge, also adversely impacts its ability to penetrate
the cell and reach the mitochondrial rhodanese [10].
Considering the serious limitations of the current antidotes, several investigations
have been in progress to develop the next generation of cyanide therapeutics [64, 65, 106,
109-111]. One promising approach is the development of a sulfur-donating compound
that works effectively with or without rhodanese [64, 65]. Based on this approach,
numerous synthetic and naturally occurring sulfur donors have been evaluated for in-vitro
and in-vivo efficacy [10], with dimethyl trisulfide (DMTS) suggested as the most
promising next generation sulfur donor for treatment of cyanide poisoning. The reaction
by which DMTS detoxifies cyanide into thiocyanate is shown in Figure 2.1. The
rhodanese sulfur transfer mechanism is well-discussed in the literature [112]. However,
the mechanism of direct DMTS sulfur transfer is not well understood, but is known to
occur [73]. Moreover, the high lipophilicity of DMTS permits its effective penetration of
the cell membrane and the blood brain barrier, allowing better in-vivo antidotal efficacy
than thiosulfate [73]. Recent in vitro studies demonstrate that, compared to sodium
thiosulfate, DMTS is 43 times more effective at detoxifying cyanide in the presence of
rhodanese [73]. Whereas, in absence of rhodanese, the difference in efficacy is even
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higher, with DMTS producing 79 times greater efficacy than thiosulfate [73]. These
results are consistent with in vivo studies, where the therapeutic antidotal ratio of DMTS
was more than triple of what was observed for thiosulfate at the same dose. The in vivo
and in vitro efficacy data confirm that DMTS is a superior cyanide countermeasure
compared to the present sulfur donor therapy of thiosulfate.
Despite the potential advantages of DMTS, the lack of a validated analytical
method for its analysis may limit vital studies for therapeutic translation of DMTS. The
only relevant report in regards to analysis from a biological matrix was published by
Shirasu and coworkers, where DMTS was identified as a source of sulfurous malodor in
fungating cancer wounds [113]. However, the concentrations of DMTS were not well
quantified, and the method was not validated. Besides this single study, DMTS has
mainly been identified as a naturally occurring compound contributing to pungent odors
in vegetables such as garlic, soy, cabbage, broccoli, and cauliflower [113-117]. In
addition, it has also been detected or quantified from fermented and aged food (cheese)
and drinks (milk, beer [118], sake, and wine), where it most likely comes from oxidation
of methanethiol, a bacterial degradation product of methionine [113, 119-123]. The
analysis of DMTS is typically accomplished using headspace analysis or solid-phase
microextraction with GC-MS. While these analytical techniques provide direction for the
analysis of DMTS from blood, a validated analytical method is not currently available
(from any matrix), but is critical for further development of this promising antidote.
Therefore, the objective of the current study was to develop a validated method for the
analysis of DMTS from whole blood. To accomplish this objective, a stir bar sorptive
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extraction (SBSE) GC-MS analysis technique for analysis of DMTS from rabbit whole
blood samples was developed.
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Figure 2.1. Schematic representation of the reaction of DMTS and cyanide to form
dimethyl disulfide (DMDS) and thiocyanate.
2.2 Experimental
2.2.1 Reagents and Standards
All reagents were at least reagent grade unless otherwise noted. Methanol (LCMS grade) and nitric acid were purchased from Fisher Scientific (Fair Lawn, NJ, USA).
Reverse-osmosis water was purified to 18.2 MΩ-cm using a polishing unit from Lab Pro,
Labconco (Kansas City, KS, USA). Dimethyl trisulfide (DMTS) was obtained from
Sigma-Aldrich (St. Louis, MO, USA). Gerstel Twister® stirbars (film thickness 0.5 mm,
length 10 mm) were purchased from Gerstel, Inc. (Linthicum, MD, USA). Isotopically
labeled internal standard, dimethyl-d6-trisulfide (DMTS-d6), was acquired from US
Biological Life Sciences (Salem, MA, USA). DMTS stock solution was prepared fresh
for each experiment due to the unstable nature of DMTS. The internal standard solution
was prepared from a 10 mM stock solution in methanol stored at -30 °C.
2.2.2 Biological fluids
For method development and validation, rabbit whole blood (EDTA anticoagulated) was purchased from Pelfreeze Biological (Rogers, AR, USA) and stored at 80 °C until used. Rabbit whole blood was chosen as the method development matrix
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because we planned to utilize a rabbit model performed by our collaborators to prove the
applicability of the analytical method for the analysis of blood DMTS concentrations.
However, at the time we were finalizing the method validation, efficacy studies of DMTS
were transitioned to a mouse model. Mouse blood from DMTS efficacy studies was
gathered at Sam Houston State University. DMTS was intramuscularly administered at
200 mg/kg. The mice were anesthetized (after 10 and 15 min) and placed on isoflurane.
Blood was collected intravenously using a heparinized Pasteur pipette and transferred to
heparinized 1.5 mL centrifuge tubes. An aliquot of blood (~150 µL) was then frozen and
shipped on dry ice to South Dakota State University. Upon receipt, samples were stored
at -80 °C until ready for analysis. Due to the limited volume of mouse blood, the sample
(100 µL) was transferred to a clean vial and diluted in DI water to 500 µL before
extraction and analysis.
All animals were handled in accordance with the Guide for the Care and Use of
Laboratory Animals [124] by an Association for the Assessment and Accreditation of
Laboratory Animal Care (AAALAC) International accredited institution. The
Institutional Animal Care and Use Committee (IACUC) at Sam Houston State University
approved the experiment.
2.2.3 Sample preparation
Blood (450 µL) was added to a 20 mL glass scintillation vial. An aliquot of
aqueous nitric acid (1 mL, 90 mM) was added to the blood to lyse the red blood cells and
denature the blood proteins. Where appropriate, aqueous DMTS standard (25 µL) was
spiked into the denatured blood to achieve the desired final DMTS concentration.
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Whenever needed, internal standard (25 µL) was spiked into the prepared blood to
produce a final concentration of 5 µM DMTS-d6. A PDMS (poly dimethyl siloxane)
coated stir bar was then added to the mixture, the sample was capped, and stir bar
sorptive extraction was performed for 1 h at 700 rpm. Following extraction, the stir bar
was removed from the solution using a 2-inch Teflon-coated magnet. The stir bar was
gently dried by dabbing against a delicate task wipe and then transferred into a Thermal
Desorption Unit (TDU) tube. The TDU tube was then placed into an auto-sampler for
follow-on thermal desorption and GC-MS analysis. (Note: Because of the rapid
enzymatic degradation of DMTS in blood, for all validation experiments, blood was acid
denatured before adding DMTS or IS in order to maintain the reported concentration
and minimize error occurring from the rapid decomposition. The reported concentration
of all DMTS standards, including QCs and calibrators, excludes the acid dilution
volume.)
2.2.4 GC-MS analysis of DMTS
After SBSE, stir bars were analyzed for DMTS and DMTS-d6 using an Agilent
Technologies 7890A gas chromatograph with a 5975C inert XL electron
ionization/chemical ionization mass selective detector with a Gerstel MPS 2XL series
autosampler. To initiate analysis of the stir bar, the TDU tube with stir bar was
transferred to the TDU injector and heated to transfer DMTS to the cooled injection
system (CIS). The initial TDU injector temperature was maintained at 60 °C, and
increased linearly to 250 °C at a rate of 720 °C/min. The final TDU injector temperature
of 250 °C was maintained for 1 min. Desorbed analytes were transferred to the CIS
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programmable temperature vaporization (PTV) type inlet in splitless desorption mode
with a TDU transfer temperature of 200 °C. To transfer the analyte from the CIS to the
GC column, the initial CIS temperature (30 °C) was linearly increased to 200 °C at a rate
of 12 °C/s before returning to its initial temperature. Lower CIS temperatures, 10 and 0
°C, were evaluated. However, improvement of the chromatography was not observed,
likely due to the relatively high boiling point of DMTS (170 °C).
A DB5-MS bonded-phase column (30 m x 0.25 mm I.D., 0.25 µm film thickness;
J&W Scientific, Folsom, CA, USA) was used to separate components of the sample with
nitrogen as the carrier gas at a flow rate of 1 mL/min and a column head pressure of
5.565 psi. The GC oven temperature was initially held at 30 °C for 1 min, then elevated
at a rate of 120 °C/min to 250 °C, where it was held constant for 1 min, before returning
to its initial temperature. The elapsed time from adding the TDU tube to TDU to the end
of the analysis was ~ 9 min, which included transfer of the analyte from the PDMS
coated stir bar, through the TDU and CIS, and into the column. The actual
chromatographic acquisition time was 3.83 min with DMTS and DMTS-d6 eluting at 2.9
min. The GC was interfaced with a mass selective detector using electron ionization with
an electron energy of 70 eV. The MS source and quadrupole temperatures were 250 °C
and 150 °C, respectively. Selective ion monitoring (SIM) was used to monitor the
quantification and identification ions of DMTS (m/z of 126 and 111, respectively) and
DMTS-d6 (m/z of 132 and 114, respectively).
2.2.5 Calibration, quantification, and limit of detection
Validation of this method was performed by generally following the Food and
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Drug Administration guidelines [125-127]. For calibration and quality-control (QC)
standards, a combined DMTS and IS aqueous solution was initially prepared to limit loss
of DMTS (i.e., loss from evaporation and degradation). Aqueous DMTS standard (100
µL) was transferred via pipette to a 2 mL glass vial, and a cap with a septum was used to
immediately seal the vial. To the closed vial, IS (100 µL of 200 µM) was injected using a
1 mL (0.33 x 12.7 mm) syringe, and subsequently mixed to produce a combined standard
of DMTS and IS. This standard solution was refrigerated at 4 °C until it was used for the
preparation of calibration or QC standards. (Note: Mixing of DMTS and IS in a closed
vial using a syringe was a crucial step to prevent the rapid and uneven evaporative loss
of DMTS and IS when opening and closing vials. Additionally, it was important to
introduce IS and DMTS to the blood simultaneously to account for the rapid enzymatic
degradation of DMTS.) Calibration and QC standards were prepared by spiking the
combined standard (25 µL) into 1475 µL of denatured blood and extracting as previously
described in the sample preparation section. Each calibration standard (0.5, 1, 2, 5, 10,
20, 50, and 100 µM) was prepared in triplicate. To obtain a calibration curve, the average
peak-area signal ratios of DMTS to IS were plotted as a function of concentration. Peak
areas were calculated by manual integration from baseline to baseline in ChemStation
software (Agilent Technologies, Santa Clara, CA). Five preliminary calibration curves
were constructed to evaluate the calibration behavior of DMTS. Ultimately, a total of ten
calibration curves constructed over the course of preliminary studies and validation
experiments confirmed that a non-linear power curve fit (y=axb) best described the
calibration behavior of DMTS.
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The limit of detection (LOD) was determined by analyzing multiple
concentrations of DMTS in blood below the LLOQ. The LOD was defined as the lowest
DMTS concentration that reproducibly produced a signal-to-noise ratio of 3. Noise was
measured by averaging the peak-to-peak noise in blank over the retention time of the
analyte. The lower limit of quantification (LLOQ) and upper limit of quantification
(ULOQ) were defined as the lowest and highest concentrations that satisfied the inclusion
criteria of <15% relative standard deviation (as a measure of precision), and a percent
deviation within ±15% back-calculated from the nominal concentration (as a measure of
accuracy) for all calibration standards within the dynamic range. QC standards were
prepared and analyzed in quintuplicate at three concentrations not included in the
calibration curve: 1.5 µM (low QC), 7.5 µM (medium QC), and 35 µM (high QC). QCs
were prepared fresh daily in order to calculate the intra-assay (within same day) and
inter-assay (over three separate days, within six calendar days) accuracy and precision.
2.2.6 Selectivity and sensitivity
The ability to differentiate and quantify DMTS in the presence of other blood
components (assay selectivity) was determined by comparing blank blood with DMTS
spiked blood. The absence of signals above the baseline in the blank over the elution time
of DMTS was indicative of high selectivity.
Short- and long-term stability of DMTS was assessed by analyzing triplicates of
low and high QCs in rabbit blood at different storage conditions over multiple time
periods. For short-term stability, prepared QCs were evaluated in the autosampler, on the
bench-top, and under multiple freeze-thaw (FT) cycles. The autosampler stability was
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evaluated by storing PDMS stir bars after SBSE extraction on the autosampler (at
ambient temperature), and analyzing them at approximately 0, 1, 5, 10, and 24 h. Internal
standard was not used for the autosampler stability experiment, as it would correct for the
loss of DMTS during the storage time tested. The bench-top stability was evaluated for
two different conditions: non-denatured blood and denatured blood. The low and high
QCs for both conditions were allowed to stand at room temperature for 0, 1, 2, 4, 8, 12,
and 24 h prior to analysis.
For freeze-thaw stability of DMTS, four sets of QCs (low and high) were
prepared. One set of QCs was extracted and analyzed on the same day while the other
three sets were stored in a freezer at -80 °C. After 24 h, all three sets of QCs were thawed
by running ambient tap water over the base of the sample vial. A single set of thawed
QCs was then extracted and analyzed, while the remaining two sets were again stored at 80 °C for 24 h. The procedure was repeated two more times to evaluate three freeze-thaw
cycles.
Evaluation of long-term stability in blood was conducted at three storage
conditions (-80, -20, and 4 °C). The low and high QCs were analyzed in triplicate on the
day they were prepared, and after 1, 2, 5, 10, and 30 days. A simple experiment was also
performed to test if loss of DMTS would be minimized by snap freezing of blood
samples before storage. Triplicates of high QCs in blood were prepared and snap-frozen
using a dry ice–acetone bath before storing them at -80 °C. The recovery of these samples
was compared to non-snap frozen samples also stored at -80 °C. For bench-top, freezethaw, and long-term stability experiments, internal standard was spiked into the blood
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samples after completion of the storage period and prior to SBSE extraction to correct for
sample preparation and instrument variability. We also evaluated the long-term stability
of DMTS in PDMS-coated stir bars at -80 °C. For this experiment, all stir bars were
extracted at the same time from a single denatured solution (50 mL blood, 100 mL 90
mM HNO3) of appropriate QC concentration (low and high). For each QC solution,
fifteen PDMS stir bars (triplicates for 5 storage days) were anchored on a 3-inch
cylindrical magnetic stir bar, which was used to stir the denatured blood solution for 1.5 h
to perform SBSE. After extraction, the PDMS stir bars were transferred into 2 mL glass
vials and capped. The stir bars were analyzed on the day they were prepared, and after 1,
5, 10, and 40 days. Since IS could not be used for this experiment, triplicate of a 5 µM
aqueous DMTS solution was prepared, extracted using SBSE, and analyzed on each day
the QCs were evaluated for stability in order to correct for instrument variability over
different days. For all stability experiments, stability was calculated as a percentage of
the initial “time-zero” signal. DMTS was considered stable if the stored sample
percentage was within 10% of time zero.
Finally, to verify if the IS corrects for the loss of DMTS during storage and
sample preparation, a 5-day stability test was performed. The QCs (low and high) were
prepared by spiking the combined standard of DMTS and IS, and were stored at -80 °C
for 1, 2, and 5 days. When ready to analyze, the QCs were thawed, denatured with acid,
and extracted using SBSE. The DMTS/IS ratio for each day was calculated and compared
to Day 0.
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2.2.7 Recovery and matrix effects
Recovery of DMTS was evaluated by analyzing triplicates of low, medium, and
high aqueous QCs, and comparing them with the equivalent QCs in blood. Recovery was
calculated as a percentage by dividing the analyte signal in blood by the aqueous signal.
Recovery calculated in this manner will be influenced by blood matrix effects, and
therefore, may not reflect a true estimate of recovery. A true recovery from blood cannot
be measured discretely, but may be estimated once matrix effects are assessed. Matrix
effects were assessed by comparing the aqueous calibration curve with the calibration
curve of DMTS in blood. The deviation of b in the power-fit equation (y=axb) gave a
measure of the magnitude of the matrix effects.
2.3 Results and Discussion
2.3.1 GC-MS analysis of DMTS from rabbit blood
The method presented here includes an easy one-pot sample preparation scheme
for extraction of DMTS from whole blood. The whole blood is simply treated with acid
to lyse RBCs and denature proteins, and then a PDMS stir bar is directly added to the
resulting solution. After an hour of SBSE, the stir bar is then analyzed via GC-MS by
thermally desorbing the DMTS in the TDU.
SBSE was chosen for sample preparation of DMTS because it has a relatively
high phase ratio, SBSE is a single-step solventless process, and it is typically highly
reproducible [128]. Specifically, the analysis of DMTS using SBSE takes advantage of
the relatively high octanol-water distribution co-efficient of DMTS (log Kow = 1.87).
Assuming equilibrium is reached and the Kow of DMTS is a good estimate of the KPDMS,

35
approximately 54% of the DMTS should reside in the PDMS layer of the stir bar (film
thickness 0.5 mm, length 10 mm), when the sample volume is 1.5 mL (i.e., the final
sample volume used in the current method). The overall sample preparation time is 1 h 10
min, with thermal desorption and chromatographic analysis lasting approximately 15 min
(including equilibration time for the following sample). Using this method, roughly 90
individual samples could be processed and analyzed in a 24 h time period.
The total ion chromatogram (TIC) of blank rabbit blood and selected ion
chromatograms (m/z = 111, 114, 126 and 132) of spiked (1 µM DMTS and 1 µM IS)
blood are plotted in Figure 2.2. The peaks for DMTS and IS eluted at approximately 2.9
min. The method showed excellent selectivity with no interfering or co-eluting peaks in
the blank. Quantification ions of DMTS (m/z of 126) and IS (m/z of 132), and
identification ions of DMTS (m/z of 111) and IS (m/z of 114) are plotted in Figure 2.2.

36

Figure 2.2. Total ion GC-MS chromatograms of non-spiked blood (lower trace, listed as
“Blank”) and selected ion chromatograms of 1 µM DMTS (middle traces) and 1 µM
DMTS-d6 (upper traces). DMTS quantification and identification ions (m/z 126 and 111,
respectively) and DMTS-d6 quantification and identification ions (m/z 132 and 114,
respectively) are separately plotted.
2.3.2 Dynamic range, limit of detection, and sensitivity
Calibration curves for DMTS were constructed in the range of 0.2 – 200 µM in
rabbit blood. Upon analysis of multiple calibration curves using linear (non-weighted and
weighted), power, and quadratic fits, we determined that the calibration behavior of
DMTS followed a power curve (y=axb). Using a power fit, 0.2 and 200 µM calibrators
did not meet the accuracy and/or precision inclusion criteria, and were excluded.
Therefore, the dynamic range for the method was from 0.5 µM (LLOQ) to 100 µM
(ULOQ), with a correlation co-efficient (R2) > 0.998. The b term of the calibration
equation (y=axb) remained consistent over the three calibration curves, producing a
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relative standard deviation of within ≤2%, and confirming the uniform calibration
behavior of DMTS (Table 2.1).
The dynamic range of the method spanned over two orders of magnitude, which is
typically good for analysis from biological samples [129, 130], and should be useful for
therapeutic studies where a large range of concentrations is administered. The method
achieved an excellent LOD, 60 nM in blood, as compared to other similar methods for
therapeutics [70, 106, 130]. The low limit of detection is most likely attributed to the
efficient pre-concentration of DMTS in the PDMS layer of the stir bar.
The non-linear behavior of DMTS was verified by over than 10 calibration curves
produced with the method presented here from both blood and aqueous samples, and
from direction injection of DMTS calibration standards. Non-linear calibration behavior
when directly injecting DMTS calibration standards, suggests that the non-linearity did
not stem from the extraction process or from the matrix components. This behavior is
most likely caused by either higher concentrations of DMTS enhancing the MS ionization
process (i.e., more DMTS molecular ions are produced as the concentration of DMTS in
the ionization chamber increases) or adsorptive losses at low DMTS concentrations (i.e.,
a small amount of high affinity sites binding DMTS, with greater amounts of DMTS
overwhelming these high affinity sites). Evaluation of the peak shape and calibration
behavior of the low and high concentration calibrators indicated no evidence of
adsorptive losses. Therefore, it is most likely that the ionization of the DMTS molecular
ion, the ion used for quantification, is enhanced at higher concentrations. This may occur
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if DMTS molecular ions assist in ionization of more DMTS molecules through energy
transfer, similar to chemical ionization.
Table 2.1. Curve equations and R2 values for separate calibration curves prepared over a
three-day period.
Days
Day 1
Day 2
Day 3

Equation
y = 0.1184x1.18
y= 0.1321x1.21
y= 0.1232x1.19

R2
0.9984
0.9992
0.9984

2.3.3 Accuracy and precision
The accuracy and precision of the method, as determined by quintuplicate
analysis of low (1.5 µM), medium (7.5 µM), and high (35 µM) QCs, on three different
days (within a 6-day period), are reported in Table 2.2. Considering that DMTS is
vulnerable to rapid enzymatic degradation and evaporative loss, the accuracy and
precision of the method were remarkable. The intra-assay accuracy (±7-14%) and
precision (<2-10% RSD), and inter-assay accuracy (±11%) and precision (<6% RSD) of
this method were excellent and well within the FDA method validation guidelines [125127, 129].
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Table 2.2. The accuracy and precision for the analysis of DMTS in spiked rabbit blood
by SBSE-GCMS.
Intra-assay
Concentration
(µM)

Accuracy (%)a

Inter-assay
Precision
(%RSD)a
Day Day Day
1
2
3
9.4
6.3
2.1
0.9
0.6
1.1
0.7
1.2
1.3

Day
Day
Day
1
2
3
1.5
100±12.5 100±6.7 100±13.5
7.5
100±0.1 100±0.2 100±8.3
35
100±6.5 100±7.6 100±6.5
a
QC method validation (N=5)
b
Mean of three different days of QC method validation (N=15)

Accuracy
(%)b

Precision
(%RSD)b

100±10.8
100±2.8
100±6.9

5.9
4.9
0.6

2.3.4 Matrix effects and recovery
The assessment of matrix effects provides a measure of ion suppression or
enhancement leading to loss or gain of analyte signal. It is typically calculated by
comparing the slope of the calibration curve in blood with that of the aqueous calibration
curve. For a non-linear power trend, the power (b) in y = axb translates to the slope in a
linear fit. Hence, matrix effects were evaluated by calculating the ratio of power
coefficient of the calibration curve in blood to that in aqueous. This ratio, determined as
0.96, indicated that matrix effects were essentially negligible for the analysis of DMTS in
blood. The minimal matrix effect can be attributed to the fact that only hydrophobic
analytes (log Kow > 2) are efficiently extracted into the PDMS-coated stir bar. This
minimizes the interference from other blood components during DMTS analysis. Note
that the power coefficients of IS-corrected aqueous and blood calibration curves, were
even closer to each other (Powerblood/Poweraq = 0.998), which gives another indication of
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effectiveness of the IS in correcting for any loss of DMTS signal during the analysis
process.
Assay recovery of DMTS for low, medium, and high QCs was 66, 63, and 59%
respectively. Incomplete recovery can be partly attributed to the rapid enzymatic
degradation of DMTS in blood. Although the acid concentration and volume were
optimized for the best recovery, the acid-denaturation process may not suffice in
completely halting all enzymatic activity. Additionally, lower recovery can also be
explained by the hydrophobic nature of DMTS. Since some components of blood provide
a more hydrophobic environment than water, these components may interfere with
effective partitioning of DMTS into the PDMS layer of the stir bar. Nevertheless, the
recovery for all low, medium, and high QCs was very consistent, and sufficient to
achieve detection at concentrations as low as 60 nM. It is unlikely that lower recovery is
caused from evaporative loss, since both the aqueous and blood samples undergo same
sample preparation steps. Therefore, loss of DMTS from evaporation should be
comparable.
2.3.5 DMTS storage stability
The bench-top stability of DMTS was evaluated for low and high QCs in both
non-denatured and denatured blood for 0, 1, 2, 4, 8, 12 and 24 h. At 1 h, DMTS was
undetectable in the non-denatured blood, whereas 65% of the signal was recovered from
the denatured blood. This observation confirms that enzyme metabolism and protein
binding comprise a key loss mechanism for DMTS. Although DMTS was detectable in
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the denatured blood, it is still considered unstable (<90% of the original signal was
recovered) at 1h.
Auto-sampler stability, following stir bar extraction of DMTS, was tested for 0, 1,
5, 10, and 24 h, during which, DMTS was stable for the 24 h time period tested (i.e., the
DMTS signals at different time periods randomly deviated above and below the time zero
signal; the variability was likely caused by differences between stir bars and slight
changes in instrument sensitivity over time).
Long-term stability was evaluated for low and high QCs by storing them at -80, 20, and 4°C over a 30-day period. DMTS was rapidly removed from blood when stored
at -20 and 4 °C, with less than 10% signal recovered after one day relative to the initial
time. However, at -80 °C, although some of the DMTS signal was lost (20-50%), the
concentration stayed consistent over the 30 day period with no trend of further loss. The
rapid loss at higher temperatures (-20 and 4 °C) likely results from the enzymatic activity
of blood proteins. At -80 °C, the rapid initial loss may have resulted from DMTS
degradation during the delay times between spiking DMTS and complete freezing, and/or
during thawing prior to acid addition. In order to reduce the initial delay time of complete
freezing, blood samples were snap frozen using dry ice and acetone bath before
transferring to a -80 °C freezer. Results from this experiment showed similar recovery for
the snap frozen (79 ± 9.6%) and non-snap frozen (72 ± 12.8%) samples. This suggested
that the significant loss mainly takes place during the thawing process, and that snap
freezing prior to storage does not provide a definite advantage.
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Long-term stability of DMTS in the stir bar was evaluated at -80 °C for 0, 1, 5,
10, and 40 days to determine if the samples could be prepared and the stir bars analyzed
at a later date. The signal ratio of DMTS to positive control was determined to compare
the stability of DMTS over different days. The high QCs were stable in the stir bar for 5
days (i.e. signal within ±10%), whereas, the low QCs were considered unstable on Day 5.
On Day 40, both QCs (high and low) were considered unstable with signal loss of 3040%.
The freeze-thaw stability test showed that DMTS is lost with each freeze-thaw
cycle, which was in agreement with our findings from long-term stability of DMTS in
blood at -80 °C. During the freeze-thaw cycle, DMTS is rapidly lost from the blood likely
due to the enzymatic activity. Hence, freezing and thawing should be avoided, but if
freezing the blood is necessary, then acid should be added immediately after thawing in
order to help preserve DMTS.
The 5-day stability study using QCs (low and high) showed that when IS was
spiked before the storage, the DMTS to IS ratio remained consistent throughout the
storage time, verifying that the IS effectively corrected for any loss of DMTS during
storage. Figure 2.3 shows the ability of the IS to correct for signal loss during storage.
Figure 2.3A illustrates DMTS stability without IS correction, where DMTS signal is seen
to significantly deviate compared to the Day 0 signal. Figure 2.3B shows the DMTS to IS
signal ratio for all days. When comparing these two graphs, it is obvious that the IS
corrects for the large signal loss due to instability of the DMTS.
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Overall, our results from the stability studies suggest that blood samples should be
denatured with acid, spiked with IS, extracted and analyzed immediately whenever
possible. In any circumstance where immediate analysis is not possible, the blood
samples should be spiked with IS, frozen as soon as possible, and stored at -80 °C for
future analysis. Once the frozen samples are thawed, they should be prepared and
extracted immediately. Once extracted into the PDMS layer, DMTS is stable for at least
24 h on the auto-sampler at ambient temperature. While the DMTS is stable in the stir bar
at -80 °C for 24h, it is not recommended to store the stir bar under these conditions unless
it is absolutely necessary.

Figure 2.3. Evaluation of the ability of the IS to correct for signal loss during storage at 80 °C. (A) DMTS signal stability plotted without IS correction. (B) IS corrected DMTS
signal stability. The uncorrected DMTS signal clearly decreases from Day 0 (due to l loss
during storage and freeze-thaw process) and has high variability (due to variation in
instrument sensitivity and stir bars). The IS corrected stability remains consistent
throughout the time tested, with the IS correcting the DMTS signal for significant loss
mechanisms.
2.3.6 Analysis of DMTS exposed animals
The validated SBSE GC-MS method was applied to the analysis of DMTS from blood
samples of treated mice. The GC-MS chromatograms of treated and untreated mouse
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blood are shown in Figure 2.4. DMTS was detected as a prominent peak at 2.9 min from
DMTS- treated mouse blood, whereas no peak was present in the untreated blood. This
further verified the selectivity of the method and confirmed its applicability to real-world
samples.

Figure 2.4. GC-MS chromatograms (SIM, m/z 126) for DMTS treated (200 mg/kg) and
untreated mice blood, and DMTS spiked and non-spiked rabbit blood.
2.4 Conclusion
A simple and sensitive analytical method for the determination of the DMTS in blood
was developed using SBSE-GCMS. The method presented is the first validated method
for DMTS analysis from any matrix. The described method is simple, with easy one-pot
sample preparation and extraction. The method yielded excellent accuracy and precision,
consistent recovery, minimal matrix effects, an excellent detection limit, and a large
dynamic range that spanned over 2 orders of magnitude. The ability to store internal
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standard spiked samples was also demonstrated. The creation of this method is
significant, since there are no analytical methods currently available for analysis of
DMTS from blood. The availability of this method will allow further drug development
investigations of DMTS as a promising cyanide antidote.
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Chapter 3. Identification of sulfur mustard biomarkers for correlation to inhalation
studies
3.1 Introduction
Sulfur mustard, bis (2-chloroethyl) sulfide, is a potent vesicant that has been a
continued threat as a warfare agent since its first use in World War I [131, 132]. SM has
caused more casualties than all other chemical weapons combined [3] and remains the
most utilized chemical weapon [131, 133, 134]. For example, during the Iraq-Iran war
(1980-1988), over 1,000 tons of SM was used in the battlefields by Iraq resulting in over
100,000 injuries [135, 136]. To this date, more than two decades later, there are still
30,000 of these war victims needing treatment for SM poisoning [137, 138].
SM can enter the body via inhalation, ingestion (of contaminated food),
cutaneous, and ocular routes [132]. Exposure can result in short- and long-term health
effects, which can include ocular and dermal injury, respiratory tract damage,
neurotoxicity, reproductive and developmental toxicity, gastrointestinal effects,
hematological effects, cancer, and death [3]. Although SM has a wide range of toxic
effects, airway injury is the principal cause of mortality in victims [11].
Injuries from SM inhalation are concentration-dependent. In humans, exposure to
low or moderate inhalation dose of SM affects mainly the upper respiratory tract, and can
cause nasal mucosal injury, lacrimation, rhinorrhea, loss of smell and taste, and acute
edema formation [3, 6, 139]. At high concentrations, injury of greater severity can extend
to larynx, sinuses, trachea, bronchi, and other distal regions [3, 6]. Tracheobronchial
mucosal sloughing, severe airway edema, ulceration, and formation of fibrin-rich
obstructive bronchial casts is seen to occur, which can ultimately lead to fatal outcomes,
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including sudden death [3, 6]. Despite its severity, the pathology of airway obstruction is
not well understood, and unfortunately, no therapies exist to prevent or alleviate the fatal
effects of inhalation exposure. In order to improve the understanding of inhalation
toxicity and to properly evaluate and develop effective clinical interventions, animal
model studies that accurately replicate the physiological injuries induced by inhalation of
SM is desired. Currently, there are only limited number of SM inhalation studies, and a
few therapeutic approaches that are under investigation [12].
One of the major challenges of inhalation studies is to accurately deliver a
targeted dose [140]. Unlike oral or parenteral routes (i.e. intravenous, cutaneous, subcutaneous), the delivered dose in inhalation studies depends on several parameters, such
as exposure concentration, breathing frequencies, tidal volume, minute volume,
deposition pattern within various regions of respiratory tract [140]. Therefore, in order to
confirm/accurately monitor the inhalation dose, a biomarker of exposure (toxin or its
byproduct) can be analyzed from a biological specimen of an individual and related to the
inhaled dose [141, 142]. The advantage of using a biomarker of exposure to calculate
dose is that it estimates the actual “internal” dose of exposure, and also improves
reliability of the study by adding internal validity when examining outcome of the
exposure [141].
The reaction pathways and breakdown products for SM are presented in Figure
3.1. SM initially undergoes intramolecular cyclization to form a positively charged
ethylene episulphonium ion intermediate [3, 132]. This cyclic intermediate can then
undergo oxidation or hydrolysis or can react with nucleophiles in the body (e.g.
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glutathione, proteins, and DNA). A direct oxidation results in β-chloroethyl sulfoxide
(SMO), direct hydrolysis results in thiodigycol (TDG), and oxidation of TDG results in
thiodigycol oxide (TDGO). SM can also be detoxified via glutathione pathway, where a
molecule of SM reacts with two molecules of glutathione. The bis-glutathione is then
metabolized into a bis-cysteinyl conjugate followed by β-lyase cleavage of cysteinyl C-S
bond and a subsequent methylation and oxidation of the thiol, resulting in 1,1’sulfonylbis[2-S-(N-acetylcysteinyl) ethane] (SBSNAE), 1,1’-sulfonylbis[2-(methylthio)
ethane] (SBMTE), 1-methylsulfinyl-2-[2-(methylthio)ethylsulfonyl]ethane (MSMTESE)
and 1,1’ - sulfonylbis [2-(methylsulfinyl) ethane] (SBMSE). Finally, the reactive SM
intermediate can also react with nucleophilic sites of DNA and amino acid residues in
proteins to form hydroxyethylthioethyl (HETE) adducts.
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Figure 3.1. Metabolic products of sulfur mustard: hydrolysis, oxidation, β –lyase
products, DNA (N7-HETEG, O6-HETEG, N3-HETEA, Bis-G) and protein adducts
(HETE-Val and HETE-Cys).
Given the highly reactive nature of SM, its detection as an intact agent is not very
likely. Therefore, exposure can be monitored by analyzing its metabolites and/or adducts.
The metabolism of SM has been widely studied in animal models, and a number of free
metabolites and covalent adducts with macromolecules have been identified. However,
all studies on the metabolites and their profiles have only been performed for intravenous,
cutaneous, and sub-cutaneous routes [79, 84, 89]. Although the byproducts of SM can be
expected to be the same in parenteral and inhalation routes, the relative abundance and
toxicokinetic behavior of metabolites will be dependent on factors such as penetration,
absorption, and diffusion of SM and metabolites through the different biological barriers.
Therefore, it is important that the behavior of biomarkers is known for inhalation
exposure.
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In this research, we evaluated the potential plasma metabolites of SM, and
screened them in the plasma of SM exposed (via inhalation) animals. Biomarkers that
were definitive (i.e., not present in plasma of unexposed animals) and had significant
concentrations in plasma of exposed specimen were correlated with dose.
3.2 Materials and Methods
3.2.1 Chemicals and reagents
TDG, TDGO, N-acetyl cysteine, ammonium formate, sodium thiomethoxide,
sodium thioethoxide, and 18-crown-6 were purchased from Sigma Aldrich (St. Louis,
MO, USA). Methanol, methylene chloride, ethanol, chloroform, acetonitrile, potassium
permanganate, sodium periodate, hydrogen peroxide, sulfuric acid, nitric acid, sodium
bicarbonate, ethanol, hydrochloric acid, and sodium chloride were purchased from Fisher
Scientific (Hampton, NH, USA).
For method validation, swine plasma (with EDTA) was purchased from Pelfreeze
Biologicals (Rogers, AZ) and rat plasma (Sprague Dawley with sodium citrate was
purchased from BioreclamantionIVT (New York, NY, USA)
3.2.2 Synthesis of metabolites
Apart from TDG and TDGO (purchased from Sigma Aldrich), all of the other SM
metabolites, and the internal standard (SBESE) were synthesized in house according to
previously published methods [143, 144]. The synthesis procedures for all metabolites
are briefly explained in the following sections. An overall reaction scheme is presented in
Figure 3.2. Note that SM, needed for the synthesis of SMO was only produced in situ and
immediately oxidized.
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3.2.2.1 Synthesis of 1,1’-sulphinylbis(2-chloroethane) (SMO)
Thiodiglycol (1 g) was dissolved in 15 mL of methylene chloride, to which 2 g
(2.1 eq.) of thionyl chloride in 15 mL of methylene chloride was added drop-wise. The
reaction was stirred for 30 min at room temperature (rt) to generate sulfur mustard in situ.
Concentrated nitric acid (0.52 g, 1 eq.) was added drop-wise and the reaction was stirred
for 30 min at rt. The final reaction mixture was transferred to a separatory funnel and
washed with water. The organic layer was dried under vacuum using a rotary evaporator,
which yielded a white solid of SMO (1.3 g, 92%). NMR 1H 400MHz, CDCl3 δ 2.1 (s,
6H) 3.0 (t, 4h) 3.3 (t, 4H).
3.2.2.2 Synthesis of 1,1’-sulfonylbis [2-(methylthio) ethane] (SBMTE)
SMO (1.3 g) was dissolved in 20 mL of water. Concentrated sulfuric acid (1.7
mL, 1.3 eq.) and 1.3 g of potassium permanganate was added to the SMO solution. The
reaction mixture was refluxed for 3 h and cooled to rt. The mixture was then diluted with
20 mL of water and extracted with methylene chloride (3x20 mL). The organic layer was
washed with aqueous sodium bicarbonate and aqueous sodium chloride. The final organic
layer was dried under vacuum using a rotary evaporator. A white solid of sulfur mustard
sulfone (SMO2, 0.94 g, 66%) was obtained as the residue.
Sulfur mustard sulfone (1.1 g) was dissolved in 30 mL of ethanol. Sodium
thiomethoxide (1.32 g, 3.3 eq.) and 9 mg (5 mol%) of 18-crown-6 was added to the
mixture. The reaction was stirred at rt overnight. Once the starting material disappeared
(TLC 1:9 MeOH:CHCl3), 10 mL of 1 M hydrochloric acid was added to quench the base,
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and 10 mL of water was added to dilute the mixture. The reaction mixture was allowed to
stand for 30 min to allow methanethiol to evaporate. The product was extracted with
methylene chloride (4x50 mL). The organic layer was washed with aqueous sodium
bicarbonate and aqueous sodium chloride, and was dried under vacuum. SBMTE yielded
as a yellow solid (1g, 81%). NMR 1H 400MHz, CDCl3 δ 2.1 (s, 6H) 2.9 (t, 4h) 3.2 (t,
4H).
3.2.2.3 Synthesis of 1-methylsulfinyl-2-[2-(methylthio) ethylsulphonyl] ethane
(MSMTESE)
In a 25 mL round bottom flask, 150 mg (1 eq.) of SBMTE was dissolved in 1:1
H2O: MeOH. Sodium periodate (160 mg, 1.1 eq.) was added and the reaction was stirred
at rt for 4 h. The reaction mixture was filtered and the filtrate was evaporated under
vacuum, which yielded a white solid of MSMTESE (137 mg, 85%). NMR 1H 400MHz,
CDCl3 δ 2.2 (s, 3H) 2.7 (t, 3H), 3.0 (t, 2H), 3.1 (t, 2H), 3.4 (t, 2H), 3.6 (t, 2H).
3.2.2.4 Synthesis of 1,1’-sulfonylbis [2-(methylsulfinyl) ethane] (SBMSE)
In a 100 mL round bottom flask, 200 mg (1 eq.) of SBMTE was suspended in
water, and 0.6 mL of 30% peroxide (6 eq.) was added. The reaction was allowed to
proceed at room temperature until little starting material remained (TLC chloroformmethanol 9:1). Sodium sulfite (1 g) was dissolved in the mixture to quench the remaining
peroxide. The reaction product was extracted in methylene chloride (3x30 mL), and was
dried over sodium sulfate and evaporated under vacuum. The product collected,
(SBMSE, 162 mg) was a white solid (71%). NMR 1H 400MHz, CDCl3 δ 2.7 (s, 6H), 3.2
(t, 4H), 3.6 (t, 4H).
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3.2.2.5 Synthesis of 1,1’-sulfonylbis [2-S-(N-acetylcysteinyl) ethane] (SBSNAE)
In a 100 mL round bottom flask, 400 mg of SMO2 (1 eq.) and 720 mg of Nacetylcysteine (2.1 eq.) were suspended in 8 mL of water. To the mixture, 0.8 mL of
triethylamine (TEA) was added and the reaction was stirred at rt for 2h. The reaction
mixture was acidified to pH of 3 using 1 M HCl and placed in the refrigerator overnight.
A white colored precipitate formed was vacuum filtered; reaction yield was 70%. NMR
1

H 400MHz, D2O δ 1.1 (t, 4H). 1.2 (t, 4H), 2 (s, 6H), 3.1 (d, 4H), 3.5 (t, 2H).

3.2.2.6 Synthesis of 1,1’-sulfonylbis [2-(ethylsulfinyl) ethane] (SBESE)
In a 100 mL round bottom flask, 200 mg (1 eq.) of SMO2 was dissolved in 10 mL
of ethanol, and sodium thioethoxide (1.85 g, 2.1 eq.) and 10 mg (5 mol%) of 18-crown-6
was added to the mixture. The reaction was stirred at rt overnight. Water (10 mL) and
470 mg of sodium periodate (2.1 eq.) were added to the mixture. The organic layer was
evaporated, leaving a white solid of SBESE. NMR 1H 400MHz, CDCl3 δ 1.4 (t, 6H) 2.9
(q, 4H), 3.2 (t, 4H), 3.6 (t, 4H).
3.2.3 Characterization of prepared standards
A Bruker Avance 400 MHz NMR was used to characterize the compounds and
confirm their purity. The NMR data are presented in the synthesis section for each
metabolite. The standards were also analyzed via direct infusion in the mass
spectrometer. Based on the information provided by Li et al. [89], the precursor and
product ions were identified and verified for each analyte to further confirm the identity
of the synthesized standards.
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3.2.4 Sample preparation
Sample preparation for the analysis of metabolites was based on Li et al. [89],
with a few modifications. Plasma (100 µL, spiked or non-spiked) was added to a 2 mL
centrifuge tube. To the plasma, internal standard (400 µL, 0.25 µM) in a mixed solution
of acetonitrile-methanol (4:1) was added. The mixture was vortexed and then coldcentrifuged at 8 °C for 15 min at 14,000 rpm. The supernatant was then transferred into a
vial and evaporated to dryness under N2. The residue was reconstituted with 50 µL of
water, filtered using 0.22 µm tetrafluoropolyethylene membrane syringe filter into
autosampler vials with 200 µL glass inserts for HPLC-MS-MS analysis.
3.2.5 UHPLC-MSMS analysis
Prepared samples were analyzed using a Shimadzu UHPLC (LC-20 AD,
Shimadzu Corp., Kyoto, Japan) coupled to a 5500 Qtrap Mass Spectrometer (AB Sciex,
Farmingham, MA, USA) with electrospray ion source. The LC parameters were based on
Li et al. paper with few modifications in gradient and total chromatographic runtime [89].
Separation of 10 µL of prepared sample was performed using Agilent Zorbax Eclipse
C18 column (100 mm x 3 mm x 1.8 µm) protected by a Agilent Zorbax Eclipse Plus C18
guard column (2 mm x 5 mm x 1.8 µm) (both Agilent, Santa Clara, CA, USA). Mobile
phase solutions consisted of an aqueous 5 mM ammonium formate with 1% methanol
(Mobile Phase A) and 5 mM ammonium formate in 95% methanol (Mobile Phase B).
The flow rate was maintained at 0.3 mL/min. The percentage of B was 0, 5, 17, 50, 80,
and 0 at 0, 1.5, 2.5, 5, 8, and 10 min, respectively. The total chromatographic run-time
was 10 min, with a 3 min equilibration time between runs.
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The mass spectrometric detection was performed in positive polarity in multiple
reaction monitoring (MRM) mode. The MRM transitions for each analyte was selected
based on their scan spectra obtained from infusion analysis of each standard. Collision
energy (CE), declustering potential (DP), and collision cell exit potential (CXP) were
optimized for each MRM transition. The dwell time for all MRM transitions were 100
ms. Nitrogen gas (30 psi) was used as the curtain and nebulization gas. The ion source
was operated at 5000 V and 500 °C. The collision cell was operated at entrance potential
of 10 V, with a high collision gas pressure.
3.2.6 Detection of biologically relevant levels from spiked plasma
Prior to analysis of animal samples from an inhalation exposure study, the lowest
biologically relevant levels for all plasma metabolites were estimated based on
toxicokinetic data from SM sub-cutaneous exposure of rats by Li et al. [89]. Once
estimates of the relevant levels were established, plasma samples were spiked with the
relevant concentrations of all metabolites and analyzed. During this process, analysis of
SBMTE was eliminated because of literature evidence of its low significance in previous
studies, and difficulty in analysis.
3.2.7 Screening of metabolites from exposed swine plasma
Inhalation exposure studies were conducted on four (1 control, 3 SM exposed;
weights between 46-50 kg) Yorkshire SPF Oak Hill female swine at MRIGlobal, Kansas
City, MO. The experiments were conducted in accordance with the Guide for the Care
and Use of Laboratory Animals [124] by an Association for the Assessment and
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Accreditation of Laboratory Animal Care (AAALAC) International accredited institution.
The Institutional Animal Care and Use Committee (IACUC) approved the experiment.
Swine were intubated with an endotracheal tube attached at 90° to a plenum
where mustard gas was passed through at positive pressure. Animals were sedated and
allowed to breathe spontaneously on the system. The targeted exposure dose was 200
mcg/kg, exposure time was variable depending on respiratory rate and tidal volume.
Blood draws were taken through an arterial line placed on femoral artery. Plasma samples
were prepared via standard procedures and shipped in dry ice. Upon receipt, samples
were stored at -80 °C until analyzed.
After analysis, the concentrations of most promising biomarkers were calculated
using external standardization (Note: Internal standard was not available when this study
was performed). Toxicokinetic profile was studied by plotting time versus ln
(concentration). The kinetic model of the marker was identified and rate constant of
elimination (kel) and half-life (t1/2) were calculated.
3.2.8 Validation of the method for SMO and SBSNAE in swine plasma
After screening plasma samples from the exposed swine, only those metabolites
that showed potential to be used as definitive markers were selected for further analysis.
Therefore, validation parameters were only evaluated for SMO and SBSNAE.
Stock solutions (10 mM) of SMO, SBSNAE, and SBESE (IS) were prepared
separately in acetonitrile and stored at -30 °C. During the time of analysis, fresh working
solutions were prepared from the stock.
The limit-of-detection (LOD) was determined by evaluating triplicates of multiple
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low concentrations (0.1 nM – 50 nM) for SMO and SBSNAE in plasma. The lowest
concentration that reproducibly produced a signal-to-noise ratio (with noise estimated as
peak-to-peak noise) of at least 3 compared to blank plasma samples was confirmed as the
LOD.
Matrix-matched calibration curves were produced in swine and rat plasma. The
lower and upper limits of quantification were defined with the inclusion criteria of <20%
for relative standard deviation (RSD) and accuracy of 100±20% of the nominal calibrator
concentration back calculated from the calibration curve. Calibration standards were
prepared by serial dilution of a composite stock solution (100 µM; SMO and SBSNAE)
in plasma. Calibration standards were prepared from 0.02-10 µM (0.02, 0.05, 0.1, 0.2,
0.5, 1, 2, 5, 10 µM). Refer to Section 2.4 for detailed sample preparation. Calibration
curves were generated by plotting concentration versus peak area ratio of analyte (SMO
or SBSNAE) to internal standard (SBESE). To determine accuracy and precision of the
calibration curve, quintuplicates of low (0.15 µM), medium (0.75 µM), and high (3 µM)
QCs were analyzed. Calibration standards and QCs were prepared fresh each day during
intra-assay (daily) and inter-assay (over three separate days, within seven calendar days)
analyses to calculate intra-assay and inter-assay accuracy and precision.
LODs, linear range, and intra-assay accuracy and precision were also evaluated
for rat plasma. Because no differences were observed between the rat and swine plasma,
determination of inter-assay accuracy and precision was not pursued for rat plasma. Other
validation parameters such as recovery, stability, and matrix effect were already
evaluated by Li et al. and hence were not repeated here [89].
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3.2.9 Analysis of rat plasma samples for biomarker correlation to inhalation dose
The animal exposure studies were conducted on Sprague Dawley rats at
University of Colorado, Denver. Experiments were conducted in accordance with the
Guide for the Care and Use of Laboratory Animals [124] by an Association for the
Assessment and Accreditation of Laboratory Animal Care (AAALAC) International
accredited institution. The Institutional Animal Care and Use Committee (IACUC)
approved the experiment.
Rats were anesthetized with a combination of ketamine (100 mg/kg) and xylazine
(10 mg/kg), i.m. After induction of anesthesia, a laryngoscope was used to visualize the
larynx to facilitate tracheal intubation. A piece of PE 90 tubing was used as a guide for
the endotracheal tube. Rats were intubated with a modified glass Pasteur pipette (ca. 5 cm
long) to a point in the trachea between the larynx and the bifurcation of the trachea. A
glass endotracheal tube was necessary to minimize absorption of SM. The tube was then
secured in place by gently wrapping a piece of porous tape around the tube and rostrum
of the rat. Sulfur mustard in absolute ethanol (100 µl) or ethanol alone (control) was
placed in a water-jacketed (37 °C) glass vapor generator (custom fabricated by Atmar
Glass, Kennett Square, PA, USA) and the rats were connected to this device and exposed
for 50 min. By the end of the exposure period, the SM in ethanol was completely
vaporized and inhaled. This passive exposure system included an inlet one-way
respiratory check valve (Hans Rudolph, Inc., Kansas City, MO, USA) to ensure that the
only source of air for the animal during the exposure was through the vapor generator.
Exhaled air passed out of a 2200 series two-way non-rebreathing Rudolph valve and
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through a charcoal-filtered bleach trap to decontaminate any exhaled SM. At the
conclusion of the 50-min exposure, the rats were disconnected from the vapor generator,
the endotracheal tube was removed and the rats were returned to their cages. The mustard
concentration in ethanol was calculated based on average weights of animals in the study
and exposure dose groups (1.2, 2.5, and 4.0 mg/kg). Rats were euthanized via anesthesia
and blood was drawn from the descending aorta upon death. Plasma was separated from
blood and shipped on dry ice. Upon arrival samples were stored at -80 °C until analyzed.
3.3 Results and Discussion
3.3.1 LCMSMS analysis of plasma metabolites
The MRM transitions along with optimized CE, DP, and CXP values for all
metabolites of interest and internal standard are listed in Table 3.1. The total
chromatographic time for the LCMSMS method was 10 minutes. A representative
chromatogram with all metabolites of interest is shown in Figure 3.3. The quantitation
ion XICs of the blank and spiked plasma for each analyte are plotted for the duration of
their elution time.
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Table 3.1. Optimized parameters for MRM transitions for SM metabolites of interest.
Analyte
TDGO

MRM Transitions
139 à 77a
139 à 63
SBMSE
247 à 183a
247 à 119
SBSNAE
445 à 130
445 à 357a
TDG
123 à 105a
105 à 87
MSMTESE
231 à 75
231 à 167a
SMO
175 à 63
175 à 59a
SBESE (IS)
297 à 141a
297 à 297
a:
Transition for quantitative ion.

CE (V)
22
18
15
29
35
30
9
9
20
15
29
38
25
10

DP (V)
50
50
50
50
55
50
50
50
50
50
103
118
13
4

CXP (V)
8
10
16
16
21
29
10
10
10
16
11
11
9
6
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Figure 3.3. Extracted ion chromatograms (XICs) of six plasma metabolites of SM plotted
over the time of their elution. Non-spiked swine plasma is shown in the lower trace,
whereas the upper trace shows plasma spiked with metabolites.
3.3.2 Detection of metabolites at biologically relevant levels
Metabolites spiked at biologically relevant levels were analyzed to ensure capability of
the method for their detection. According to the toxicokinetic plasma profiles from a subcutaenous study in rats, the lowest relevant levels for direct metabolites, SMO, TDG, and
TDGO were 0.3 µM, 0.4 µM, and 40 nM respectively, and for β-lyase metabolites,
SBMTE, SBMSE, MSMTESE, and SBSNAE were 0.09 nM, 0.4 nM, 0.4 nM, and 0.2
nM respectively. TDG, TDGO, SMO, SBMSE, and MSMTESE were detected at the
lowest relevant levels from spiked plasma. However, SBMTE and SBSNAE could not be
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detected at the lowest biological levels. According to Li et al. SBMTE was a very minor
biomarker (lowest cmax), with concentrations at or below LLOQ for the most time-points
tested. Because of its low importance, SBMTE was eliminated for further analysis. The
lowest concentration of SBSNAE was calculated at the time-points before 1h, where the
marker has a very low presence in plasma. The profile for SBSNAE increases
significantly after 2 h, and has the highest concentration between 2-6 h post-exposure.
Therefore, even though SBSNAE couldn’t be detected at lowest levels at early timepoints, it should be detected quantitatively at greater time-points (2-6 h). Therefore,
because SBSNAE is an important β-lyase metabolite and it produces concentrations
above the method LOD for most time-points, it was not eliminated.
3.3.3 Identification of metabolites from exposed swine plasma
Plasma samples of swine exposed to SM via inhalation were analyzed for TDGO,
SBMSE, SBSNAE, MSMTESE, TDG, and SMO. Among the metabolites of interest,
only three (TDGO, SBSNAE, and SMO) were consistently detected from the exposed
animals, whereas other metabolites such as TDG, SBMSE, and MSMTESE were not
detected.
TDG, which is a direct metabolite, was not detected in any of the samples, even
though TDGO was. This is partially attributed to the low sensitivity of TDG in the
LCMSMS. Yet, TDG was detected at large concentrations in rat plasma after subcutaneous exposure by Li et al. [89] Therefore, the more likely explanation is that the
inhalation route provides a different oxidation environment than cutaneous/sub-cutaneous
routes. A greater oxidizing environment likely results in facile conversion of TDG into
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TDGO, and SM to SMO, lowering the concentration of TDG in plasma to undetectable
levels.
SBMSE and MSMTESE may not have been detected because the blood draws for
the animal samples spanned only up to 3 hours post-exposure. Unlike, TDGO and SMO,
which are direct products of oxidation and hydrolysis of SM, β-lyase metabolites are
formed by several steps of biological mechanisms, and hence take longer time to appear
in the plasma. Additionally, results from published toxicokinetic studies suggest that βlyase metabolites like SBMSE and MSMTESE also have very low plasma concentrations
(low cmax). Therefore, the low concentrations and longer onset of these markers could
attribute to the inability in their detection.
SBSNAE, which is also a β-lyase marker, was detected in all swine plasma
samples from the inhalation study. This is in agreement with the previously published
toxicokinetic studies, because among all the β-lyase metabolites, SBSNAE has the
highest cmax and faster onset. Unlike SBMSE and MSMTESE that require further
cleavage of the cysteinyl residues and subsequent oxidation of terminal sulfides to
sulfoxides, SBSNAE is formed in fewer metabolic steps after the glutathione
conjugation, and hence, can be detected at earlier time-points than SBMSE and
MSMTESE.
Among the three detected metabolites (SMO, TDGO, and SBSNAE), only SMO
and SBSNAE can be used as definitive marker. Previous studies have suggested the
presence of TDGO at low levels (2-8 ng/mL) in biological specimen of unexposed
animals and humans [87, 145]. Because of the endogenous levels that can be dependent
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on diet, environment, and other variables, the use of TDGO as a marker for correlation to
dose would not be ideal.
The toxicokinetic profiles for SMO and SBSNAE are presented in Figures 3.4 and
3.6 respectively. SMO appeared in the plasma samples immediately and reached the
highest level (cmax) before 1 h post-exposure. This behavior observed from inhalation
exposure in swine mimics the behavior from sub-cutaneous exposure in rats. The plot of
time vs. ln (concentration) for SMO for individual swine is shown in Figure 3.5. The
slopes for the three animals were similar to each other. SMO followed a onecompartment distribution model which indicates its rapid equilibration throughout the
body. The rate constant for the elimination (kel) of SMO was calculated as 0.97±0.15 h-1,
and the t1/2 was 0.73 ±0.12 h. The SBSNAE was observed only after 30 min time-point,
and its level gradually and continually increased to 4 h, at the final draw. According to
toxicokinetics in sub-cutaneous study, SBSNAE should have a cmax at 4 h. Unfortunately,
the animal samples from inhalation study did not extend over 4 h, and hence the complete
profile could not be studied for SBSNAE. However, the results observed for both SMO
and SBSNAE are in good agreement with the findings of Li et al. [89].
SMO and SBSNAE can be used as ideal markers for determination of SM
exposure. Both metabolites are absent in unexposed samples and can be used as
unequivocal confirmation for SM. Moreover, both metabolites have dominant presence in
exposed samples, especially during the first 6 h (latency period of SM poisoning). SMO
also has a potential to be used as a diagnostic marker immediately (within 15 min) after
exposure. Both of these markers should be further evaluated to determine if they can be
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used to correlate to inhalation dose.
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Figure 3.4. Toxicokinetic profile of SMO in swine plasma for inhalation exposure of
SM. 19109, 19595, and 19596 designate the three individual animals used for the study.
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Figure 3.5. Plot of time vs. ln (concentration) for the individual swine (19109, 19595,
and 19596). The slopes for each animal were similar to each other. The elimination of
SMO followed a one-compartment distribution model.
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Figure 3.6. Toxicokinetic profile of SBSNAE in swine plasma for inhalation exposure of
SM. 19109, 19595, and 19596 designate the three individual animals used for the study.
3.3.4 Validation of the method for SMO and SBSNAE in swine plasma
Validation parameters (LOD, linear range, accuracy and precisions) were only
evaluated for SMO and SBSNAE. LOD for SMO was determined as 10 nM in both swine
and rat plasma, whereas LOD for SBSNAE was 5 nM and 10 nM for rat and swine
plasma respectively. Representative chromatograms for LODs in rat plasma are presented
in Figures 3.7 and 3.8.
The linear ranges for SMO (0.05 µM - 5 µM) and SBSNAE (0.05 µM - 10 µM)
covered at least two orders of magnitude in both types of plasma (swine and rat).
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Calibration curve used 1/x2 weighted fitting. Intra-assay accuracies for all QCs were
within 100±18% % for SMO and SBSNAE, whereas intra-assay precisions for all QCs
were <20 %RSD for both SBSNAE and SMO. Inter-assay accuracies for SMO were
within 100 ±17% and within 100±7% for SBSNAE. The inter-assay precision was <13
%RSD for both metabolites. Because the type of plasma did not affect the validation
parameters, intra-assay accuracy and precision were evaluated only for one day in rat
plasma. Accuracies and precisions for all QCs are listed in Table 3.2 and 3.3 for
SBSNAE and SMO respectively.
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Figure 3.7. LOD for SBSNAE analysis in swine plasma. The lower trace shows nonspiked swine plasma, whereas the upper trace shows 10 nM spiked swine plasma. The
LOD concentration (10 nM) reproducibly produced S/N of at least 3.
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Figure 3.8. LOD for SMO analysis in swine plasma. The lower trace shows non-spiked
swine plasma, whereas the upper trace shows 10 nM spiked swine plasma. The LOD
concentration (10 nM) reproducibly produced S/N of at least 3.
Table 3.2. Intra- and inter- assay accuracies and precisions for analysis of SBSNAE in
spiked swine plasma.
Concentration
(µM)

a
b

Intra-assay
Accuracy (%)

a

Precision (%RSD)

a

Inter-assay
Accuracy Precision
(%)b
(%RSD)b

Day1

Day2

Day3

Day1

Day2

Day3

0.15

100±4.8

100±8.1

100±13.5

14.2

5.0

2.1

100±1.2

11.5

0.75
3

100±16.8
100±4.3

100±1.5
100±2.1

100±8.3
100±6.5

3.1
2.2

5.0
4.2

1.1
1.3

100±6.2
100±3.4

9.6
4.0

QC method validation (N=5)
Mean of three different days of QC method validation (N=15)
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Table 3.3. Intra- and inter- assay accuracies and precisions for analysis of SMO in spiked
swine plasma.
Concentration
(µM)

a
b

Intra-assay
Accuracy (%)

a

Precision (%RSD)

a

Inter-assay
Accuracy Precision
(%)b
(%RSD)b

Day1

Day2

Day3

Day1

Day2

Day3

0.15

100±17.1

100±16.7

100±9.3

19.1

6.8

3.5

100±16.4

12.6

0.75
3

100±13.6
100±9.3

100±6.7
100±10.5

100±0.4
100±0.9

12.2
6.2

6.5
6.1

6.8
1.6

100±13.2
100±5.8

9.3
12.8

QC method validation (N=5)
Mean of three different days of QC method validation (N=15)

3.3.5 Correlation of biomarker concentration to inhalation dose in rats
Rat plasma samples collected at 1, 2, 3, and 7 h from inhalation exposure in three
different dose groups (1.2, 2.5, and 4.0 mg/kg) were analyzed. Dose versus peak area
ratio (SMO/IS) for SMO at 1 h time-point is plotted in Figure 3.9; error bars represent
standard error of the mean (n=3). The SMO concentration showed a linear increase with
the dose (R2 = 0.98). Similarly, the dose versus peak area ratio (SBSNAE/IS) for
SBSNAE at 7 h time-point is plotted in Figure 3.10. SBSNAE concentration also showed
a linear increase with dose, with R2 value of 0.99. Although these preliminary data
indicate linear correlation of exposure dose with metabolite concentration, more detailed
study with larger sample size (n > 5) at each dose would be required to verify the
correlation. Additionally, more time-points (before, at, and after Cmax) should be
investigated for both markers in order to determine the optimal time-point that can be
used for dose correlation. Here, the plotted data are for time-points where Cmax of the
analyte should already be achieved. Note that the Cmax time-point for SMO and SBSNAE
is estimated as 0.6 and 4 h respectively; the plotted data (Figures 3.9 and 3.10) are at 1 h
for SMO and 7 h for SBSNAE.
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Figure 3.9. Linearity of peak area ratio (SMO/IS) to exposed SM concentrations at 1 h
time-point.
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Figure 3.10. Linearity of peak area ratio (SBSNAE/IS) to exposed SM concentrations at
7 h time-point.
3.4 Conclusion
Six plasma metabolites (TDG, TDGO, SBMSE, MSMTESE, SBSNAE, and SMO) of
SM were investigated for their potential as biomarkers in inhalation studies. Exposed
swine plasma samples from an inhalation study were screened for determination of ideal
metabolites for correlation to inhalation dose. Only three metabolites, TDGO, SBSNAE,
and SMO, were consistently detected, and only two (SMO and SBSNAE) could be used
as unequivocal markers of exposure. Toxicokinetic behavior for SMO and SBSNAE were
found to be in good agreement in inhalation and sub-cutaneous exposure. Preliminary
data from inhalation studies showed a linear correlation of SMO and SBSNAE with SM
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concentration. However, detailed studies with greater number of animals will be
important to confirm the correlation. A good correlation will allow use of these
biomarkers to calculate the “actual internal dose” in inhalation studies. This is the first
reported investigation of SM biomarkers from an inhalation study.
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Chapter 4. Analysis of sulfur mustard oxide in plasma using chemical ionization – gas
chromatography mass spectrometry
4.1 Introduction
Conflicts around the world have made chemical warfare agents (CWAs), such as
2,2’-dichloro diethyl sulfide (sulfur mustard), a significant threat to mankind.
Technological advancement, globalization, easy access to raw materials and technical
information, and increased government-sponsored terrorism have proliferated the
prospects of chemical terrorism in the modern world [13]. Although joint international
efforts have led to destruction of many declared chemical stockpiles, these efforts have
not been fully effective in preventing the use of CWAs such as mustards, sarin, cyanide,
etc. by terrorist organizations or countries such as Iraq and Syria [1, 5, 146, 147].
After World War II, some of the most catastrophic uses of CWAs occurred during
Iran-Iraq conflict. Within the time frame of late 1980s to early 1990s, Iraq allegedly used
a combination of CWAs, including sulfur mustard, against Iranian soldiers and its own
Kurdish people, resulting in an estimated 50,000 fatalities [5]. More recently, between
2013-2017, over 1400 deaths occurred from use of CWAs by Assad regime on Syrian
people [4]. These tragic developments in recent times have established an increasing need
to develop and improve analytical methodologies to confirm exposure in concerned
individuals.
Sulfur Mustard (SM) is a potent vesicant that produces blisters upon exposure
and also causes injury to the respiratory system, eyes, and bone marrow [5, 148, 149].
Additionally, it is a strong alkylating agent that can have long-term mutagenic and
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carcinogenic effects. At high doses, SM can cause fatality within days or weeks primarily
due to severe airway obstruction caused by formation of pseudomembranes in respiratory
tract [6, 132, 148-152]. However, death can also occur from second-degree burns and
multi-organ failure [6, 152, 153]. At medium and low doses, the toxicity depends on
concentration and duration of exposure, and can result in short- and long-term injury
[147]. The clinical effects of both high and low dose SM exposure are characterized by
an initial asymptomatic latent period of 6-24 h before the development of pain and
lesions [147, 154, 155]. This delayed onset results in delay for clinical diagnosis and
treatments. Therefore, a method to rapidly and reliably diagnose SM poisoning from
potential victims during this latent period is critical [156].
Although analysis of the intact agent is the most direct diagnostic marker, the
rapid conversion of sulfur mustard in biological system limits the window-of-opportunity
to detect the intact agent [5]. Therefore, verification of exposure is more reliably
achieved by screening plasma or urine for free metabolites that are derived from direct
oxidation and hydrolysis of SM, or conjugation with glutathione followed by metabolic
conversion (β-lyase metabolites). The oxidation and hydrolysis products, namely, sulfur
mustard oxide (SMO), thiodiglycol (TDG), and thiodiglycol oxide (TDGO), appear in
plasma and urine within 15 min post-exposure [89]. While several methods have been
produced to determine TDG and TDGO using gas chromatography-mass spectrometry
(GC-MS) or gas chromatography-tandem mass spectrometry (GC-MS/MS) [84, 88],
TDG and TDGO cannot be used as unequivocal markers for SM exposure because of
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their presence at low concentrations (0-1 ng/mL for TDG and 2-8 ng/mL for TDGO) in
samples from unexposed animals [87, 145].
Furthermore, although β-lyase metabolites can be used for definite confirmation
of exposure, and several analytical methods using GC-MS or liquid chromatographytandem mass spectrometry (LC-MS-MS) are available [83, 89, 157], these metabolites
appear in plasma and urine only after 1-2 h post-exposure. Moreover, the β-lyase
metabolites are also present at very low concentrations. In a toxicokinetic study
performed by Li et al. for subcutaneous injection in rats, the Tmax for β-lyase metabolites
in plasma occurred between 4-8 hours post-exposure. The Cmax for most β-lyase
metabolites ranged between (1-9 µg/L), whereas one of the β-lyase metabolites was
below the quantification range of the method (5 µg/L) [89]. In a separate study with
cutaneous application of SM in rats, similar results were obtained, with peak levels of
hydrolysis and β-lyase products found at 15 min and >1 h respectively [84]. Notably, the
concentrations of the β-lyase metabolites (2.5-5.3%) accounted for lower percentage of
the applied dose compared to hydrolysis products (3.7-13.6%). The slow rise in β-lyase
metabolite concentration and their low Cmax makes them not ideal for early diagnostic
purposes. [84]. The drawbacks of the hydrolysis and β-lyase metabolites for diagnostic
analysis indicate the need for a marker that is definitive, has early onset, and has a
significant presence in biological specimen of exposed victim.
The oxidative metabolite of SM, sulfur mustard oxide (SMO) has received less
attention as a potential SM diagnostic marker. This is likely because most toxicokinetic
studies were performed using urine, and SMO is only present as a minor urinary
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metabolite [79, 82]. However, recent toxicokinetics data reported by Li et al. shows that
SMO is an important metabolite in plasma. It is an early marker with Tmax of 0.8 h postexposure [89]. SMO is also present at higher concentrations (Cmax of > 430 µg/L)
compared to β-lyase metabolites (1-9 µg/L) [89]. Additionally, unlike TDG and TDGO,
SMO is not an endogenous substance, and hence, its existence is a definite evidence of
SM poisoning [82]. Since SMO has been minimally studied, there are limited analytical
methods for its determination, especially from plasma. There are only two reported
methods for analysis of SMO from plasma, both using LC-MS-MS for detection [89,
158]. Both methods require over 1-1.5 hours for overall analysis (sample preparation and
detection). Additionally, one of the reported methods also requires chemical conversion
of SMO with 2-(3,5-bis(mercaptomethyl)phenoxy) acetic acid into a stable derivatized
product [158]. There are currently no GCMS methods for SMO analysis in the literature.
Therefore, in this paper, we present a rapid and simple sample preparation and direct
analysis scheme for SMO using chemical ionization (CI)-GCMS for diagnosis of SM
poisoning during the latent period between SM exposure and the appearance of clinical
symptoms. The availability of this method will allow rapid diagnosis of SM exposure in
victims.
4.2 Materials and Methods
Caution: SMO and SMO-d4 are reactive agents. These agents should be handled
in well-ventilated hoods. The use of gloves and stringent protective measures should be
adopted.
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4.2.1 Chemicals and solutions
For method development and validation, swine plasma (EDTA anti-coagulated)
was purchased from Pelfreeze Biological (Rogers, AR, USA) and stored at -80 °C until
used.
Thiodiglycol, 1,2-dichloroethane-d4, and 2-mercaptoethanol were obtained
from Sigma Aldrich (St. Louis, MO, USA). Hydrochloric acid, nitric acid, acetonitrile,
methylene chloride were obtained from Fisher Scientific (Fair Lawn, NJ, USA). SMO
and SMO-d4 were synthesized in the lab. Reverse-osmosis water was purified to 18.2
MΩ-cm using a Lab Pro polishing unit from Labconco Kansas City, KS, USA.
The structures for SMO and SMO-d4 are provided in Figure 1. For synthesis of
SMO, a one-pot reaction scheme was developed. Thiodiglycol (1 eq.) was reacted with
concentrated hydrochloric acid (9 eq.) at 90 °C for 90 mins. The upper aqueous layer was
removed, and concentrated nitric acid (15 eq.) was added to the reaction flask and stirred
at room temperature for 30 mins. The reaction mixture was diluted with 15 mL water and
SMO was extracted with 20 mL methylene chloride. The purity was tested with NMR, 1H
400MHz, CDCl3 δ 2.1 (s, 6H) 3.0 (t, 4h) 3.3 (t, 4H).
For synthesis of SMO-d4, sodium metal (0.15 g) was added to dry methanol (5
mL), to which 2-mercaptoethanol (0.45 mL) was added and allowed to react for 30 mins
at room temperature with occasional swirling. 1,2-dichloroethane-d4 (3.85 mL) was
added to the mixture, and the resulting solution was left in the refrigerator overnight. The
solution was filtered, and the filtrate was dried under vacuum using a rotary evaporator.
Concentrated hydrochloric acid (4 mL) was added to the residue in the flask and the
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remainder of the reaction was carried out as mentioned above. Purity of the product was
tested with GCMS (>99% purity).
4.2.2 Sample preparation
An aliquot of 500 µL plasma (spiked or non-spiked) was pipetted into a 2 mL
glass vial, to which 50 µL of aqueous 100 µM internal standard (SMO-d4) was added and
vortexed for 30 seconds. To the plasma solution, 500 µL of methylene chloride was
added for liquid-liquid extraction. The mixture was shaken for 10 s and centrifuged at
6000 rpm for 2 minutes for separation of plasma and organic layers. For centrifugation,
the glass sample vial was opened and placed into a 5 mL centrifuge tube. Note that
plastic vials and centrifuge tubes must be avoided because components in the plastics
leached into the solvent (methylene chloride) and interfered with the analysis of SMO.
After centrifugation, vials were removed from the tubes using forceps and the upper
plasma layer was carefully removed. A small layer of precipitated proteins formed
between the plasma and organic layer, which was also carefully removed without
disturbing the lower organic layer. The organic layer was then pipetted into a new 2 mL
GC autosampler vial. The organic layer was dried by blowing air, and reconstituted with
25 µL of acetonitrile. The final acetonitrile solution was transferred to a tapered-bottom
glass insert (300 µL) in a GC vial and analyzed via CI-GCMS.
4.2.3 GC-MS analysis of SMO
Prepared samples were analyzed for SMO and SMO-d4 using Agilent
Technologies 6890N gas chromatograph and a 5975B inert XL electron ionization
(EI)/chemical ionization (CI) mass selective detector (MSD) in CI with a 7683 series
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autosampler. A DB5-MS bonded-phase column (30 m x 0.25 mm I.D., 0.25 µm film
thickness; J&W Scientific, Folsom, CA, USA) was used with hydrogen as the carrier gas
at a flow rate of 1.5 mL/min and a column head pressure of 5.12 psi. The injection was
performed in splitless mode (split delay 1min, purge flow 30.1 mL/min), the injection
volume was 1 µL, and the injection port was held at 150 °C. Note that it is vital to
maintain a relatively low injection temperature in order to prevent degradation of SMO.
At higher injection temperatures, significant degradation with loss of most or all of SMO
was observed. To prevent in-column degradation, oven temperature greater than 250 °C
was not used. The initial GC oven temperature was 80 °C, which was ramped at a rate of
50 °C/min to 250 °C, where it was held constant for 1 min. The chromatographic
acquisition time was 4.40 min with SMO and SMO-D4 eluting at 2.68 min.
The GC-MSD transfer line was heated at 170 °C. The MS source and MS quad
temperatures were 250 °C and 150 °C, respectively. Methane was used as a reagent gas
for positive ion CI with electron energy of 235 eV. Selective ion monitoring (SIM) was
used to monitor the quantification and identification ions of SMO (m/z of 175 and 123,
respectively) and SMO-d4 (m/z of 181 and 127, respectively). For SMO, the major
molecular ion, m/z of 175, was selected for quantification. Because SMO has two
chlorine atoms, and Chlorine has two major stable isotopes (35Cl 75%, 37Cl 25%), its
molecular ions can exist as 175, 177, and 179. Therefore, to prevent overlap of SMO and
SMO-d4, an m/z of 181 for SMO-d4 was selected instead of 179. The structures of SMO
and SMO-d4 are presented in Figure 4.1.

82

O

A

S
Cl

Cl

B
O

D

D

S
Cl

Cl
D

D

Figure 4.1. Structures of SMO (A) and SMO-d4 (B).
4.2.4 Calibration, quantification, and limit of detection
Bioanalytical method validation was accomplished by generally following the
Food and Drug Adminisitration (FDA) guidelines [127, 129]. SMO and SMO-D4 stock
solutions (10 mM) were prepared in acetonitrile and stored at -30 °C. Aqueous solutions
of SMO were prepared via serial dilution of the stock; a working solution of 200 µM of
SMO-D4 was also prepared in water. An aqueous mix solution of SMO and SMO-D4 for
each calibrator was prepared by mixing 50:50 of SMO solution and 200 µM SMO-d4.
The mix solution was then spiked (50 µL) into plasma (450 µL) for calibration and
quality-control (QC) standards. All calibration standards (0.5, 1, 2, 5, 10, 20, 50, 100 µM)
were prepared in triplicates. To obtain a calibration curve, the average peak-area signal
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ratios of SMO to SMO-D4 were plotted as a function of concentration. Peak areas were
calculated by manual integration from baseline to baseline in ChemStation software
(Agilent Technologies, Santa Clara, CA).
For determining the upper limit of quantification (ULOQ) and lower limit of
quantification (LLOQ), a percent relative standard deviation (%RSD) of <20% (as a
measure of precision) and a percent deviation within ±20% back-calculated from the
nominal concentration of each calibration standard (as a measure of accuracy) were used
as inclusion criteria for the calibration standards. Quality control (QC) standards were
prepared in swine plasma at three different concentrations: 1.5 µM (low), 7.5 µM
(medium) and 35 µM (high). The QC standards were analyzed in quintuplicate each day
for 3 days and were run in parallel with the calibration standards. Intra-assay precision
and accuracy were calculated from each day’s analysis and inter-assay precision and
accuracy were calculated from the comparison of the data gathered from three separate
days. It should be noted that the inter-assay and intra-assay studies were conducted within
1 week. The limit of detection (LOD) was evaluated by analyzing multiple concentrations
of SMO below LLOQ, and determining the lowest concentration which reproducibly
produced a signal-to-noise ratio (S/N) (peak-to-peak) of at least 3 compared to the blank
at the same retention time.
4.2.5 Selectivity and sensitivity
Selectivity of the method was checked by analyzing blank and and spiked swine
plasma samples. A comparison of chromatograms was made among three samples of
blank plasma with three samples spiked swine (0.5 µM SMO) to determine if chemical
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components of plasma interfered with ability to quantify SMO.
For recovery experiments, detector response obtained from SMO spiked plasma
was compared to the detector response obtained for the same moles of SMO prepared in
acetonitrile. It is to be noted that in our sample preparation, the analyte is reconstituted in
a final volume of 25 µL, which allows for a 20-fold concentration increase before
analysis in GCMS. Hence, signals for triplicates of low (1.5 µM), medium (7.5 µM), and
high (35 µM) QCs in plasma were compared to the signal produced by 30, 150, and 700
µM of SMO solution in acetonitrile respectively.
4.2.6 Matrix effects
An attempt to assess the effect of matrix components to enhance or suppress the
signal of the analyte was accomplished by creating calibration curve from plasma and
aqueous solution. A ratio of less than 1 indicates suppression effect, whereas greater than
1 indicates an enhancement effect. The ratio of slopes of non-corrected curves were then
compared with the internal standard corrected curves to evaluate the effectiveness of
internal standard to minimize the matrix effect.
4.3 Results and Discussion
4.3.1 GC-MS analysis of SMO
The method presented here includes a short, simple, and direct (i.e. no chemical
modification) analysis of SMO. Using this method, a plasma sample can be prepared and
analyzed within a total analysis time of 15 min. SMO is simply extracted from plasma via
liquid-liquid extraction into methylene chloride. Different solvents were investigated to
improve extraction of SMO, such as toluene, hexane, and cyclohexane. The test solvents
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were selected with the criteria of high Kow (low miscibility with water) and low boiling
point. Among the tested solvents, methylene chloride provided the highest extraction
efficiency. The high vapor pressure of methylene chloride also allowed for extremely
rapid drying (~3 mins for 500 µL of the DCM extract) under just ambient airflow (flow
rate of ~40 mL/min). Hence, methylene chloride was chosen as the solvent of choice for
extraction from plasma samples.
Following sample preparation, the GCMS analysis was very short with a total
chromatographic runtime of less than 5 min, and SMO eluting at 2.68 min. Even with
extremely rapid and simple sample preparation and analysis, the SMO was completely
resolved from other components in the matrix, with adequate peak shape, although some
tailing is present. Representative selected ion chromatograms (SIM), m/z = 175 for SMO
and m/z = 181 for SMO-d4, of both non-spiked and spiked swine plasma is shown in
Figure 4.2. However, it is to be noted that the internal standard synthesized in-house,
SMO-d4, could attribute to some SMO ions because of its 99% purity. Therefore, for
sample analysis, blank samples spiked with only SMO-d4 should be assessed first to
calculate the level of SMO produced from the internal standard. A blank-subtraction
could potentially be performed for quantification of SMO from real samples. This could
be eliminated if a higher purity dichloroethane was used to synthesize the internal
standard. Note that in Figure 4.2, no blank subtraction was performed.

Abundance (arbitary units)
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Blank - m/z 181
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Figure 4.2. Overlay of extracted ion chromatograms (XICs) of m/z 175 (SMO) and m/z
181 (SMO-d4) for non-spiked and spiked swine plasma samples. The two lower traces
(black and green) show that there are no components in the plasma matrix that interfere
with analysis of either SMO or SMO-d4. The two upper traces (red and blue) show that
SMO and SMO-d4 elute at 2.68 min.
4.3.2 Limit-of-detection and linear range
The linearity of the method was evaluated within the concentration range of 0.2 to
500 µM. A calibration curve was constructed by plotting concentration versus corrected
signal (peak area of SMO divided by the peak area of corresponding SMO-d4). Upon
analysis of calibration standards using non-weighted and weighted (1/x and 1/x2)
calibration curves, 0.2, 200, and 500 µM standards were excluded based upon the
accuracy and/or precision criteria. The linear range of the method spanned over two
orders of magnitude, from 0.5-100 µM when using 1/x2 weighted linear regression, with
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Abundance (arbitary units)

correlation coefficient (R2) >0.998. The LOD for SMO was 0.1 µM (Figure 4.3).
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Non-spiked
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2.55
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2.65
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2.85
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Time (mins)
Figure 4.3. LOD of SMO analysis using CI-GCMS; lower trace (blue) shows nonspiked swine plasma, whereas upper trace (red) shows 0.1 µM spiked swine plasma. The
LOD concentration (0.1 µM) reproducibly produced a S/N of 3.
4.3.3 Accuracy and precision
Accuracy and precision were determined by quintuplicate analysis of low
(1.5 µM), medium (7.5 µM), and high (35 µM) QCs on three different days within 7day period. The intra-assay accuracy (100± 20%) and precision (<15% RSD) for all
QCs were within the acceptable range outlined by FDA for method validation from
biological matrix [127, 129]. The inter-assay accuracy (100 ± 13%) and precision (<
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16% RSD) were also within the acceptable criteria. The intra- and inter- assay
accuracy for low, medium, and high QCs are presented in Table 4.1.
Table 4.1. Intra- and inter- assay accuracies and precisions for analysis of SMO in spiked
swine plasma.
Concentration
(μM)

a
b

Intra-assay
Accuracy (%)a

Precision (%RSD)a

1.5

Day
1
100±16.9

Day
2
100±15.4

Day
3
100±2.7

Day
1
7.5

Day
2
14.3

Day
3
1.3

7.5
35

100±16.7
100±19.7

100±1.8
100±3.9

100±3.9
100±13.5

3.1
12.3

0.9
2.5

1.3
3.6

Inter-assay
Accuracy Precision
(%)b
(%RSD)b
100±1.4

15.7

100±6.3
100±12.1

7.8
9.5

QC method validation (N=5)
Mean of three different days of QC method validation (N=15)

4.3.4 Matrix effects
An attempt was made to assess matrix effects by evaluating the slope of
calibration curve (non-corrected) in swine plasma compared to in aqueous samples. Both
the aqueous and plasma calibrators showed a highly non-linear behavior. Therefore, the
matrix effect could not be determined. However, the matrix effect and non-linear
behavior was corrected with internal standard; the slopes of internal standard corrected
curves in plasma and aqueous were very close (ratio of 0.97). The non-corrected and
corrected calibration curves in plasma and aqueous are presented in Figure 4.4.
4.3.5 Recovery
Recovery for low, medium, and high QCs were 19%, 22%, and 23% respectively.
The low recovery can be explained by loss during liquid-liquid extraction from plasma
and also some possible loss during the drying process. The loss during extraction can be
attributed to incomplete extraction and incomplete transfer of organic layer based on
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solvent loss when removing plasma layer and loss to the vessel. However, any loss of
SMO during this process is corrected by the internal standard, with raw signals resulting
in high standard deviations (>28% RSD), whereas internal standard corrected signals
resulting in low standard deviation (<6% RSD).
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Figure 4.4. Figure showing non-corrected (A) and internal standard corrected (B)
calibration curves. Both aqueous and plasma non-corrected curves showed non-linear
behavior, and could not be compared to determine matrix effect. The ratio for slopes of
corrected plasma and aqueous curve was close to 1(slope plasma/aqueous = 0.97),
indicating that the internal standard is effective in correcting any matrix effects.
4.4 Conclusion
A GC-MS method for analysis of SMO from plasma was developed which features
very simple sample preparation, rapid analysis, wide linear range of over two orders of
magnitude, and requires no chemical modification. To our knowledge, this is the first
GC-MS method for analysis of SMO, which is an important early biomarker for sulfur
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mustard poisoning. The availability of this method should allow easy and rapid diagnosis
of sulfur mustard poisoning for potential victims.
4.5 Acknowledgements
We gratefully acknowledge the support from the CounterACT Program, National
Institutes of Health Office of the Director, and the National Institute of Environmental
Health Sciences (NIEHS), Grant number U54 ES027698 (CWW). We also want to thank
Biomedical Advanced Research and Development Authority (BARDA), Office of the
Assistant Secretary for Preparedness and Response, Office of the Secretary, Department
of Health and Human Services, under contract No. HHS0100201500020C. Furthermore,
we are thankful to Adam Pay, a graduate student at South Dakota State University for his
work on synthesizing the SMO needed for this project. The opinions or assertions
contained herein are the private views of the authors and are not to be construed as
official or as reflecting the views of the National Institutes of Health or the CounterACT
Program.

92
Chapter 5. Broader Impacts, Conclusions, and Future Work
5.1 Broader Impacts
Cyanide and SM are CWAs that pose significant global threat to mankind.
Research on improved toxicological understanding and development of effective
therapeutic interventions are crucial to defend against these CWA threats. The novel
method presented here for DMTS will allow pharmacokinetic and drug development
studies on this promising therapeutic, potentially leading to a live-saving antidote.
Additionally, metabolite studies for inhalation route of SM exposure will help identify
potential markers for calculation of “actual respiratory dose”. This would allow for
standardization of dose over different inhalation studies, improving the accuracy and
reliability of the studies. Furthermore, an easy and rapid method was developed for SMO,
an early marker of SM exposure. The availability of this method can allow for immediate
diagnosis of SM exposure in victims. The work presented here will contribute towards
development and approval of life-saving treatments for CN and SM poisoning.
5.2 Conclusions
A novel SBSE-GCMS method was developed for analysis of DMTS from blood.
The method was effective in analyzing DMTS from blood of treated animals. A simple,
direct, and rapid method was developed for analysis of SMO from plasma. The method
will allow rapid diagnosis of SM poisoning within 15 post-exposure. Plasma metabolites
for SM exposure via inhalation were identified, and correlation of metabolite
concentration with dose was investigated.
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5.3 Future Work
Future work should include pharmacokinetic studies of DMTS in various animal
models before leading to human studies. Comprehensive inhalation studies should be
done in animals for SM exposure in order to establish a correlation of biomarker
concentration to dose. Eventually, the ideal biomarker should be used to calculate “actual
dose” for inhalation studies of SM. Animal studies should be performed to confirm the
effectiveness of SMO as a diagnostic marker.
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